

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2019

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-35565

  
**AbbVie Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**32-0375147**  
(I.R.S. employer identification number)

**1 North Waukegan Road  
North Chicago, Illinois 60064**

Telephone: **(847) 932-7900**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Non-Accelerated Filer

Accelerated Filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.01 per share	ABBV	New York Stock Exchange Chicago Stock Exchange
1.375% Senior Notes due 2024	ABBV24	New York Stock Exchange
0.750% Senior Notes due 2027	ABBV27	New York Stock Exchange
2.125% Senior Notes due 2028	ABBV28	New York Stock Exchange
1.250% Senior Notes due 2031	ABBV31	New York Stock Exchange

As of October 29, 2019, AbbVie Inc. had 1,478,821,109 shares of common stock at \$0.01 par value outstanding.

**AbbVie Inc. and Subsidiaries**  
**Table of Contents**

**PART I. FINANCIAL INFORMATION**

	Page
Item 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	2
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	27
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	37
Item 4. CONTROLS AND PROCEDURES	38

**PART II. OTHER INFORMATION**

Item 1. LEGAL PROCEEDINGS	39
Item 1A. RISK FACTORS	39
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	39
Item 6. EXHIBITS	40

## PART I. FINANCIAL INFORMATION

### ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

#### AbbVie Inc. and Subsidiaries Condensed Consolidated Statements of Earnings (unaudited)

(in millions, except per share data)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
<b>Net revenues</b>	\$ 8,479	\$ 8,236	\$ 24,562	\$ 24,448
Cost of products sold	1,920	1,835	5,433	5,696
Selling, general and administrative	1,657	1,919	4,991	5,470
Research and development	2,285	1,268	4,865	3,834
Acquired in-process research and development	—	55	246	124
Other expense	—	—	—	500
Total operating costs and expenses	5,862	5,077	15,535	15,624
Operating earnings	2,617	3,159	9,027	8,824
Interest expense, net	420	302	1,054	825
Net foreign exchange loss	19	2	31	18
Other expense, net	177	94	2,590	411
Earnings before income tax expense	2,001	2,761	5,352	7,570
Income tax expense	117	14	271	57
<b>Net earnings</b>	\$ 1,884	\$ 2,747	\$ 5,081	\$ 7,513
<b>Per share data</b>				
Basic earnings per share	\$ 1.27	\$ 1.81	\$ 3.41	\$ 4.81
Diluted earnings per share	\$ 1.26	\$ 1.81	\$ 3.41	\$ 4.79
Weighted-average basic shares outstanding	1,481	1,511	1,480	1,556
Weighted-average diluted shares outstanding	1,483	1,515	1,483	1,561

The accompanying notes are an integral part of these condensed consolidated financial statements.

**AbbVie Inc. and Subsidiaries**

**Condensed Consolidated Statements of Comprehensive Income (unaudited)**

(in millions)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
<b>Net earnings</b>	\$ 1,884	\$ 2,747	\$ 5,081	\$ 7,513
Foreign currency translation adjustments, net of tax expense (benefit) of \$(16) for the three months and \$(10) for the nine months ended September 30, 2019 and \$3 for the three months and \$(16) for the nine months ended September 30, 2018	(256)	30	(288)	(250)
Net investment hedging activities, net of tax expense (benefit) of \$45 for the three months and \$53 for the nine months ended September 30, 2019 and \$(9) for the three months and \$22 for the nine months ended September 30, 2018	156	(32)	184	73
Pension and post-employment benefits, net of tax expense (benefit) of \$7 for the three months and \$19 for the nine months ended September 30, 2019 and \$8 for the three months and \$24 for the nine months ended September 30, 2018	33	28	78	99
Marketable security activities, net of tax expense (benefit) of \$— for the three months and \$— for the nine months ended September 30, 2019 and \$— for the three months and \$— for the nine months ended September 30, 2018	(1)	—	10	(2)
Cash flow hedging activities, net of tax expense (benefit) of \$18 for the three months and \$9 for the nine months ended September 30, 2019 and \$1 for the three months and \$18 for the nine months ended September 30, 2018	31	54	(32)	248
Other comprehensive income (loss)	(37)	80	(48)	168
<b>Comprehensive income</b>	\$ 1,847	\$ 2,827	\$ 5,033	\$ 7,681

The accompanying notes are an integral part of these condensed consolidated financial statements.

**AbbVie Inc. and Subsidiaries**  
**Condensed Consolidated Balance Sheets**

(in millions, except share data)	September 30, 2019	December 31, 2018
	(unaudited)	
<b>Assets</b>		
<b>Current assets</b>		
Cash and equivalents	\$ 10,648	\$ 7,289
Short-term investments	—	772
Accounts receivable, net	5,529	5,384
Inventories	1,929	1,605
Prepaid expenses and other	2,060	1,895
<b>Total current assets</b>	<b>20,166</b>	<b>16,945</b>
Investments	131	1,420
Property and equipment, net	2,894	2,883
Intangible assets, net	19,036	21,233
Goodwill	15,537	15,663
Other assets	1,677	1,208
<b>Total assets</b>	<b>\$ 59,441</b>	<b>\$ 59,352</b>
<b>Liabilities and Equity</b>		
<b>Current liabilities</b>		
Short-term borrowings	\$ —	\$ 3,699
Current portion of long-term debt and finance lease obligations	5,276	1,609
Accounts payable and accrued liabilities	12,217	11,931
<b>Total current liabilities</b>	<b>17,493</b>	<b>17,239</b>
Long-term debt and finance lease obligations	33,126	35,002
Deferred income taxes	1,058	1,067
Other long-term liabilities	15,990	14,490
Commitments and contingencies		
<b>Stockholders' equity (deficit)</b>		
Common stock, \$0.01 par value, 4,000,000,000 shares authorized, 1,781,429,626 shares issued as of September 30, 2019 and 1,776,510,871 as of December 31, 2018	18	18
Common stock held in treasury, at cost, 302,647,520 shares as of September 30, 2019 and 297,686,473 as of December 31, 2018	(24,501)	(24,108)
Additional paid-in capital	15,112	14,756
Retained earnings	3,673	3,368
Accumulated other comprehensive loss	(2,528)	(2,480)
<b>Total stockholders' equity (deficit)</b>	<b>(8,226)</b>	<b>(8,446)</b>
<b>Total liabilities and equity</b>	<b>\$ 59,441</b>	<b>\$ 59,352</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**AbbVie Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Equity (unaudited)**

(in millions)	Common shares outstanding	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Total
<b>Balance at June 30, 2018</b>	1,514	\$ 18	\$ (20,845)	\$ 14,596	\$ 5,495	\$ (2,639)	\$ (3,375)
Net earnings	—	—	—	—	2,747	—	2,747
Other comprehensive income, net of tax	—	—	—	—	—	80	80
Dividends declared	—	—	—	—	(1,453)	—	(1,453)
Purchases of treasury stock	(10)	—	(1,009)	—	—	—	(1,009)
Stock-based compensation plans and other	—	—	5	84	—	—	89
<b>Balance at September 30, 2018</b>	1,504	\$ 18	\$ (21,849)	\$ 14,680	\$ 6,789	\$ (2,559)	\$ (2,921)
<b>Balance at June 30, 2019</b>	1,478	\$ 18	\$ (24,505)	\$ 15,028	\$ 3,384	\$ (2,491)	\$ (8,566)
Net earnings	—	—	—	—	1,884	—	1,884
Other comprehensive loss, net of tax	—	—	—	—	—	(37)	(37)
Dividends declared	—	—	—	—	(1,595)	—	(1,595)
Purchases of treasury stock	—	—	(3)	—	—	—	(3)
Stock-based compensation plans and other	1	—	7	84	—	—	91
<b>Balance at September 30, 2019</b>	1,479	\$ 18	\$ (24,501)	\$ 15,112	\$ 3,673	\$ (2,528)	\$ (8,226)
<b>Balance at December 31, 2017</b>	1,592	\$ 18	\$ (11,923)	\$ 14,270	\$ 5,459	\$ (2,727)	\$ 5,097
Adoption of new accounting standards	—	—	—	—	(1,733)	—	(1,733)
Net earnings	—	—	—	—	7,513	—	7,513
Other comprehensive income, net of tax	—	—	—	—	—	168	168
Dividends declared	—	—	—	—	(4,450)	—	(4,450)
Purchases of treasury stock	(95)	—	(9,956)	—	—	—	(9,956)
Stock-based compensation plans and other	7	—	30	410	—	—	440
<b>Balance at September 30, 2018</b>	1,504	\$ 18	\$ (21,849)	\$ 14,680	\$ 6,789	\$ (2,559)	\$ (2,921)
<b>Balance at December 31, 2018</b>	1,479	\$ 18	\$ (24,108)	\$ 14,756	\$ 3,368	\$ (2,480)	\$ (8,446)
Net earnings	—	—	—	—	5,081	—	5,081
Other comprehensive loss, net of tax	—	—	—	—	—	(48)	(48)
Dividends declared	—	—	—	—	(4,776)	—	(4,776)
Purchases of treasury stock	(5)	—	(425)	—	—	—	(425)
Stock-based compensation plans and other	5	—	32	356	—	—	388
<b>Balance at September 30, 2019</b>	1,479	\$ 18	\$ (24,501)	\$ 15,112	\$ 3,673	\$ (2,528)	\$ (8,226)

The accompanying notes are an integral part of these condensed consolidated financial statements.

**AbbVie Inc. and Subsidiaries**  
**Condensed Consolidated Statements of Cash Flows (unaudited)**

(in millions) (brackets denote cash outflows)	Nine months ended September 30,	
	2019	2018
<b>Cash flows from operating activities</b>		
Net earnings	\$ 5,081	\$ 7,513
Adjustments to reconcile net earnings to net cash from operating activities:		
Depreciation	346	349
Amortization of intangible assets	1,162	974
Change in fair value of contingent consideration liabilities	2,653	432
Stock-based compensation	351	351
Upfront costs and milestones related to collaborations	341	711
Intangible asset impairment	1,030	—
Other, net	92	423
Changes in operating assets and liabilities:		
Accounts receivable	(207)	(806)
Inventories	(401)	(367)
Prepaid expenses and other assets	183	(426)
Accounts payable and other liabilities	(582)	881
<b>Cash flows from operating activities</b>	<b>10,049</b>	<b>10,035</b>
<b>Cash flows from investing activities</b>		
Acquisitions and investments	(476)	(541)
Acquisitions of property and equipment	(389)	(515)
Purchases of investment securities	(579)	(1,581)
Sales and maturities of investment securities	2,655	1,914
<b>Cash flows from investing activities</b>	<b>1,211</b>	<b>(723)</b>
<b>Cash flows from financing activities</b>		
Net change in commercial paper borrowings	(699)	(400)
Proceeds from issuance of other short-term borrowings	—	3,002
Repayments of other short-term borrowings	(3,000)	—
Proceeds from issuance of long-term debt	1,534	5,963
Repayments of long-term debt and finance lease obligations	(5)	(5,021)
Debt issuance costs	(248)	(34)
Dividends paid	(4,771)	(4,129)
Purchases of treasury stock	(627)	(9,956)
Proceeds from the exercise of stock options	6	66
Payments of contingent consideration liabilities	(120)	(78)
Other, net	36	16
<b>Cash flows from financing activities</b>	<b>(7,894)</b>	<b>(10,571)</b>
Effect of exchange rate changes on cash and equivalents	(7)	(29)
Net change in cash and equivalents	3,359	(1,288)
Cash and equivalents, beginning of period	7,289	9,303
<b>Cash and equivalents, end of period</b>	<b>\$ 10,648</b>	<b>\$ 8,015</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

# AbbVie Inc. and Subsidiaries

## Notes to Condensed Consolidated Financial Statements (unaudited)

### Note 1 Basis of Presentation

---

#### Basis of Historical Presentation

The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company's audited consolidated financial statements and notes included in the company's Annual Report on Form 10-K for the year ended December 31, 2018.

It is management's opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company's financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.

#### Recent Accounting Pronouncements

##### *Recently Adopted Accounting Pronouncements*

##### ASU No. 2016-02

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*. The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019.

The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases.

Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a \$405 million increase to other assets; (ii) a \$115 million increase to accounts payable and accrued liabilities; and (iii) a \$290 million increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant.

Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the three and nine months ended September 30, 2019.

##### ASU No. 2018-02

In February 2018, the FASB issued ASU No. 2018-02, *Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income*, which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements.

## Recent Accounting Pronouncements Not Yet Adopted

### ASU No. 2016-13

In June 2016, the FASB issued ASU No. 2016-13, *Financial Instruments - Credit Losses (Topic 326)*. The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance but does not expect a material impact on its consolidated financial statements based on the company's current portfolio of financial assets.

## Note 2 Supplemental Financial Information

### Interest Expense, Net

(in millions)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
Interest expense	\$ 480	\$ 339	\$ 1,225	\$ 968
Interest income	(60)	(37)	(171)	(143)
Interest expense, net	\$ 420	\$ 302	\$ 1,054	\$ 825

### Inventories

(in millions)	September 30, 2019	December 31, 2018
Finished goods	\$ 449	\$ 473
Work-in-process	1,120	862
Raw materials	360	270
Inventories	\$ 1,929	\$ 1,605

### Property and Equipment

(in millions)	September 30, 2019	December 31, 2018
Property and equipment, gross	\$ 8,492	\$ 8,396
Accumulated depreciation	(5,598)	(5,513)
Property and equipment, net	\$ 2,894	\$ 2,883

Depreciation expense was \$114 million for the three months and \$346 million for the nine months ended September 30, 2019 and \$115 million for the three months and \$349 million for the nine months ended September 30, 2018.

## Note 3 Earnings Per Share

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:

(in millions, except per share data)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
<b>Basic EPS</b>				
Net earnings	\$ 1,884	\$ 2,747	\$ 5,081	\$ 7,513
Earnings allocated to participating securities	10	12	27	34
Earnings available to common shareholders	\$ 1,874	\$ 2,735	\$ 5,054	\$ 7,479
Weighted-average basic shares outstanding	1,481	1,511	1,480	1,556
Basic earnings per share	\$ 1.27	\$ 1.81	\$ 3.41	\$ 4.81
<b>Diluted EPS</b>				
Net earnings	\$ 1,884	\$ 2,747	\$ 5,081	\$ 7,513
Earnings allocated to participating securities	10	12	27	34
Earnings available to common shareholders	\$ 1,874	\$ 2,735	\$ 5,054	\$ 7,479
Weighted-average shares of common stock outstanding	1,481	1,511	1,480	1,556
Effect of dilutive securities	2	4	3	5
Weighted-average diluted shares outstanding	1,483	1,515	1,483	1,561
Diluted earnings per share	\$ 1.26	\$ 1.81	\$ 3.41	\$ 4.79

Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

#### Note 4 Licensing, Acquisitions and Other Arrangements

##### Proposed Acquisition of Allergan plc

On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan) in a cash and stock transaction for a transaction equity value of approximately \$63 billion, based on the closing price of AbbVie's common stock of \$78.45 on June 24, 2019. Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and \$120.30 in cash for each Allergan share. On October 14, 2019, Allergan shareholders approved the proposed transaction.

In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a \$38.0 billion 364-day bridge credit agreement. On July 12, 2019, AbbVie entered into a term loan credit agreement with an aggregate principal amount of \$6.0 billion consisting of a \$1.5 billion 364-day term loan tranche, a \$2.5 billion three-year term loan tranche and a \$2.0 billion five-year term loan tranche, with the commitments under the bridge credit agreement to be reduced by such amount to \$32.0 billion. No amounts have been drawn under the bridge credit agreement or term loan credit agreement.

On October 25, 2019, AbbVie commenced offers to exchange any and all outstanding notes of certain series issued by Allergan for up to \$15.5 billion aggregate principal amount and €3.7 billion aggregate principal amount of new notes to be issued by AbbVie and cash, subject to conditions including the closing of the pending acquisition of Allergan. Concurrently with the offers to exchange the Allergan notes for AbbVie notes, the company solicited consents to adopt certain proposed amendments to each of the indentures governing the Allergan notes to, among other things, eliminate substantially all of the restrictive covenants in such indentures.

Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including medical aesthetics, eye care, neuroscience, gastroenterology and women's health.

The transaction is expected to close in early 2020, subject to customary closing conditions and regulatory approvals. In September 2019, AbbVie and Allergan each received a Request for Additional Information (Second Request) from the Federal Trade Commission (FTC) in connection with the transaction. AbbVie and Allergan are cooperating fully with the FTC.

### **Other Licensing & Acquisitions Activity**

Cash outflows related to other acquisitions and investments totaled \$476 million for the nine months ended September 30, 2019 and \$541 million for the nine months ended September 30, 2018. AbbVie recorded no acquired in-process research and development (IPR&D) charges for the three months ended September 30, 2019 and recorded IPR&D charges of \$246 million for the nine months ended September 30, 2019. AbbVie recorded IPR&D charges of \$55 million for the three months and \$124 million for the nine months ended September 30, 2018.

#### *Calico Life Sciences LLC*

In June 2018, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under the terms of the agreement, AbbVie and Calico will each contribute an additional \$500 million to the collaboration and the term was extended for an additional three years. Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. Following completion of Phase 2a, AbbVie will have the option to exclusively license collaboration compounds. AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. AbbVie recorded \$500 million in other expense in the condensed consolidated statement of earnings related to its commitments under the agreement during the nine months ended September 30, 2018.

#### *Reata Pharmaceuticals, Inc.*

In October 2019, AbbVie and Reata Pharmaceuticals, Inc. (Reata) entered into an amended and restated license agreement. Under the terms of the agreement, Reata reacquired exclusive development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie for territories outside of the United States with respect to bardoxolone methyl and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators. As consideration for the rights reacquired by Reata, AbbVie will receive a total of \$330 million in cash payable in three installments through 2021 which will be recognized in other income in future periods. In addition, AbbVie will receive low single-digit, tiered royalties from worldwide sales of omaveloxolone and certain next-generation Nrf2 activators.

### **Note 5 Collaboration with Janssen Biotech, Inc.**

---

In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.

The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to \$200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.

In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:

(in millions)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
United States - Janssen's share of profits (included in cost of products sold)	\$ 489	\$ 377	\$ 1,297	\$ 978
International - AbbVie's share of profits (included in net revenues)	215	160	621	455
Global - AbbVie's share of other costs (included in respective line items)	81	81	230	232

AbbVie's receivable from Janssen, included in accounts receivable, net, was \$235 million at September 30, 2019 and \$177 million at December 31, 2018. AbbVie's payable to Janssen, included in accounts payable and accrued liabilities, was \$467 million at September 30, 2019 and \$376 million at December 31, 2018.

## Note 6 Goodwill and Intangible Assets

### Goodwill

The following table summarizes the changes in the carrying amount of goodwill:

(in millions)	
Balance as of December 31, 2018	\$ 15,663
Foreign currency translation adjustments	(126)
Balance as of September 30, 2019	\$ 15,537

The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of September 30, 2019, there were no accumulated goodwill impairment losses.

### Intangible Assets, Net

The following table summarizes intangible assets:

(in millions)	September 30, 2019			December 31, 2018		
	Gross carrying amount	Accumulated amortization	Net carrying amount	Gross carrying amount	Accumulated amortization	Net carrying amount
Definite-lived intangible assets						
Developed product rights	\$ 19,600	\$ (6,208)	\$ 13,392	\$ 15,872	\$ (5,614)	\$ 10,258
License agreements	7,798	(2,154)	5,644	7,865	(1,810)	6,055
Total definite-lived intangible assets	27,398	(8,362)	19,036	23,737	(7,424)	16,313
Indefinite-lived research and development	—	—	—	4,920	—	4,920
Total intangible assets, net	\$ 27,398	\$ (8,362)	\$ 19,036	\$ 28,657	\$ (7,424)	\$ 21,233

#### Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.

In the third quarter of 2019, following the announcement of the decision to terminate the rovalpituzumab tesirine (Rova-T) research and development program, the company recorded an impairment charge of \$1.0 billion which represented the remaining value of

the IPR&D acquired as part of the 2016 Stemcentrx acquisition. No indefinite-lived intangible asset impairment charges were recorded for the nine months ended September 30, 2018.

In April 2019, the U.S. Food and Drug Administration (FDA) and the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis. As a result, AbbVie reclassified \$3.9 billion of indefinite-lived intangible assets related to SKYRIZI to developed product rights definite-lived intangible assets. This amount will be amortized over its estimated useful life using the estimated pattern of economic benefit.

#### *Definite-Lived Intangible Assets*

Amortization expense was \$389 million for the three months and \$1.2 billion for the nine months ended September 30, 2019 and \$320 million for the three months and \$974 million for the nine months ended September 30, 2018. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. No definite-lived intangible asset impairment charges were recorded for the nine months ended September 30, 2019 and 2018.

## **Note 7 Restructuring Plans**

---

AbbVie recorded restructuring charges of \$22 million for the three months and \$208 million for the nine months ended September 30, 2019 and \$22 million for the three months and \$45 million for the nine months ended September 30, 2018. Restructuring charges for the nine months ended September 30, 2019 primarily related to severance costs.

The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2019:

<i>(in millions)</i>	
Accrued balance as of December 31, 2018	\$ 99
Restructuring charges	194
Payments and other adjustments	(133)
Accrued balance as of September 30, 2019	\$ 160

## **Note 8 Leases**

---

AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.

The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option.

Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.

The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet:

(in millions)	Balance sheet caption	September 30, 2019
<b>Assets</b>		
Operating	Other assets	\$ 357
Finance	Property and equipment, net	24
Total lease assets		\$ 381
<b>Liabilities</b>		
Operating		
Current	Accounts payable and accrued liabilities	\$ 107
Noncurrent	Other long-term liabilities	268
Finance		
Current	Current portion of long-term debt and finance lease obligations	7
Noncurrent	Long-term debt and finance lease obligations	21
Total lease liabilities		\$ 403

The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings:

(in millions)	Three months ended September 30,	Nine months ended September 30,
	2019	2019
Operating lease cost	\$ 30	\$ 94
Short-term lease cost	9	24
Variable lease cost	17	46
Total lease cost	\$ 56	\$ 164

Sublease income and finance lease costs were insignificant for the three and nine months ended September 30, 2019.

The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases:

	September 30, 2019
Weighted-average remaining lease term (in years)	
Operating	6
Finance	3
Weighted-average discount rate	
Operating	4.0%
Finance	4.0%

The following table presents supplementary cash flow information regarding the company's leases:

(in millions)	Nine months ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities	
Operating cash flows from operating leases	\$ 94
Right-of-use assets obtained in exchange for new operating lease liabilities	16

Finance lease cash flows were insignificant for the nine months ended September 30, 2019.

The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of September 30, 2019:

(in millions)	Operating leases	Finance leases	Total <sup>(a)(b)</sup>
2019	\$ 32	\$ 6	\$ 38
2020	116	10	126
2021	99	9	108
2022	56	3	59
2023	35	1	36
Thereafter	80	—	80
Total lease payments	418	29	447
Less: Interest	43	1	44
Present value of lease liabilities	\$ 375	\$ 28	\$ 403

(a) Total lease payments exclude approximately \$350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years.

(b) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

## Note 9 Financial Instruments and Fair Value Measures

### Risk Management Policy

See Note 10 to the company's Annual Report on Form 10-K for the year ended December 31, 2018 for a summary of AbbVie's risk management policy and use of derivative instruments.

### Financial Instruments

Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling \$0.2 billion at September 30, 2019 and \$1.4 billion at December 31, 2018, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of September 30, 2019 will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.

In the third quarter of 2019, the company entered into treasury rate lock agreements to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the anticipated issuance of long-term debt in connection with the proposed acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and are recorded at fair value. Realized and unrealized gains or losses are included in AOCI and are expected to be reclassified to interest expense, net over the lives of the anticipated long-term debt issuances. These agreements had notional amounts totaling \$10.0 billion at September 30, 2019.

The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling \$6.2 billion at September 30, 2019 and \$8.6 billion at December 31, 2018.

The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had €3.6 billion aggregate principal amount of senior Euro notes designated as net investment hedges at September 30, 2019 and December 31, 2018. In the third quarter of 2019, the company issued €1.4 billion aggregate principal amount of senior Euro notes and designated the principal amounts of this foreign denominated debt as net investment hedges. Concurrently, the company elected to de-designate hedge accounting for €1.4 billion aggregate principal amount of existing senior Euro notes. In addition, in the second quarter of 2019, the company entered into foreign currency forward exchange contracts with notional amounts totaling €971 million, £204 million and CHF62 million and designated the instruments as net investment hedges. The company uses the spot method of assessing hedge effectiveness for

derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.

AbbVie is a party to interest rate hedge contracts designated as fair value hedges with notional amounts totaling \$10.8 billion at September 30, 2019 and December 31, 2018. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.

The following table summarizes the amounts and location of AbbVie's derivative instruments on the condensed consolidated balance sheets:

(in millions)	Fair value – Derivatives in asset position			Fair value – Derivatives in liability position		
	Balance sheet caption	September 30, 2019	December 31, 2018	Balance sheet caption	September 30, 2019	December 31, 2018
Foreign currency forward exchange contracts						
Designated as cash flow hedges	Prepaid expenses and other	\$ 4	\$ 113	Accounts payable and accrued liabilities	\$ —	\$ —
Designated as net investment hedges	Prepaid expenses and other	69	—	Accounts payable and accrued liabilities	—	—
Not designated as hedges	Prepaid expenses and other	13	19	Accounts payable and accrued liabilities	37	26
Treasury rate lock agreements designated as cash flow hedges	Prepaid expenses and other	123	—	Accounts payable and accrued liabilities	35	—
Interest rate swaps designated as fair value hedges	Prepaid expenses and other	—	—	Accounts payable and accrued liabilities	8	—
Interest rate swaps designated as fair value hedges	Other assets	44	—	Other long-term liabilities	59	466
<b>Total derivatives</b>		<b>\$ 253</b>	<b>\$ 132</b>		<b>\$ 139</b>	<b>\$ 492</b>

While certain derivatives are subject to netting arrangements with the company's counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):

(in millions)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
Foreign currency forward exchange contracts				
Designated as cash flow hedges	\$ 3	\$ 1	\$ 8	\$ 122
Designated as net investment hedges	59	—	69	—
Treasury rate lock agreements designated as cash flow hedges	88	—	88	—

Assuming market rates remain constant through contract maturities, the company expects to reclass pre-tax gains of \$50 million into cost of products sold for foreign currency cash flow hedges and pre-tax gains of \$3 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.

Related to AbbVie's non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of \$152 million for the three months and \$187 million for the nine months ended September 30, 2019 and recognized a pre-tax loss of \$41 million for the three months and a pre-tax gain of \$95 million for the nine months ended September 30, 2018.

The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI.

(in millions)	Statement of earnings caption	Three months ended September 30,		Nine months ended September 30,	
		2019	2018	2019	2018
Foreign currency forward exchange contracts					
Designated as cash flow hedges	Cost of products sold	\$ 42	\$ (54)	\$ 119	\$ (144)
Designated as net investment hedges	Interest expense, net	10	—	19	—
Not designated as hedges	Net foreign exchange loss	(55)	22	(95)	91
Interest rate swaps designated as fair value hedges	Interest expense, net	78	(63)	443	(306)
Debt designated as hedged item in fair value hedges	Interest expense, net	(78)	63	(443)	306

### Fair Value Measures

The fair value hierarchy consists of the following three levels:

- Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;
- Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and
- Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2019:

(in millions)	Total	Basis of fair value measurement		
		Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Assets</b>				
Cash and equivalents	\$ 10,648	\$ 1,288	\$ 9,360	\$ —
Debt securities	2	—	2	—
Equity securities	62	62	—	—
Interest rate hedges	44	—	44	—
Foreign currency contracts	86	—	86	—
Treasury rate lock agreements	123	—	123	—
<b>Total assets</b>	<b>\$ 10,965</b>	<b>\$ 1,350</b>	<b>\$ 9,615</b>	<b>\$ —</b>
<b>Liabilities</b>				
Interest rate hedges	\$ 67	\$ —	\$ 67	\$ —
Foreign currency contracts	37	—	37	—
Treasury rate lock agreements	35	—	35	—
Contingent consideration	6,957	—	—	6,957
<b>Total liabilities</b>	<b>\$ 7,096</b>	<b>\$ —</b>	<b>\$ 139</b>	<b>\$ 6,957</b>

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2018:

(in millions)	Total	Basis of fair value measurement		
		Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Assets</b>				
Cash and equivalents	\$ 7,289	\$ 1,209	\$ 6,080	\$ —
Time deposits	568	—	568	—
Debt securities	1,536	—	1,536	—
Equity securities	4	4	—	—
Foreign currency contracts	132	—	132	—
<b>Total assets</b>	<b>\$ 9,529</b>	<b>\$ 1,213</b>	<b>\$ 8,316</b>	<b>\$ —</b>
<b>Liabilities</b>				
Interest rate hedges	\$ 466	\$ —	\$ 466	\$ —
Foreign currency contracts	26	—	26	—
Contingent consideration	4,483	—	—	4,483
<b>Total liabilities</b>	<b>\$ 4,975</b>	<b>\$ —</b>	<b>\$ 492</b>	<b>\$ 4,483</b>

The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based on prices obtained from commercial pricing services. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At September 30, 2019, a 50 basis point increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately \$270 million. Additionally, at September 30, 2019, a five percentage point increase/decrease in the assumed probability of success across all potential indications still in development would have increased/decreased the value of the contingent consideration liabilities by approximately \$140 million.

There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs:

(in millions)	Nine months ended September 30,	
	2019	2018
Beginning balance	\$ 4,483	\$ 4,534
Change in fair value recognized in net earnings	2,653	432
Payments	(179)	(100)
Ending balance	\$ 6,957	\$ 4,866

The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. During the second quarter of 2019, the company recorded a \$2.3 billion increase in the SKYRIZI contingent consideration liability due to higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis. During the third quarter of 2019, the company recorded a \$91 million decrease in the Stemcentrx contingent consideration liability due to the termination of the Rova-T research and development program.

Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2019 are shown in the table below:

(in millions)	Book value	Approximate fair value	Basis of fair value measurement		
			Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Liabilities</b>					
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	\$ 5,284	\$ 5,293	\$ 5,286	\$ 7	\$ —
Long-term debt and finance lease obligations, excluding fair value hedges	33,141	34,964	34,943	21	—
<b>Total liabilities</b>	<b>\$ 38,425</b>	<b>\$ 40,257</b>	<b>\$ 40,229</b>	<b>\$ 28</b>	<b>\$ —</b>

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2018 are shown in the table below:

(in millions)	Book value	Approximate fair value	Basis of fair value measurement		
			Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
<b>Liabilities</b>					
Short-term borrowings	\$ 3,699	\$ 3,693	\$ —	\$ 3,693	\$ —
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	1,609	1,617	1,609	8	—
Long-term debt and finance lease obligations, excluding fair value hedges	35,468	34,052	34,024	28	—
<b>Total liabilities</b>	<b>\$ 40,776</b>	<b>\$ 39,362</b>	<b>\$ 35,633</b>	<b>\$ 3,729</b>	<b>\$ —</b>

AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was \$67 million as of September 30, 2019 and \$84 million as of December 31, 2018. No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2019.

#### Available-for-sale Securities

Substantially all of the company's investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. There were no debt securities classified as short-term as of September 30, 2019 and there were \$204 million as of December 31, 2018. Estimated fair values of available-for-sale debt securities were generally determined based on prices obtained from commercial pricing services. In the third quarter of 2019, the company sold substantially all of its investments in debt securities.

The following table summarizes available-for-sale securities by type as of December 31, 2018:

(in millions)	Amortized cost	Gross unrealized		Fair value
		Gains	Losses	
Asset backed securities	\$ 423	\$ —	\$ (2)	\$ 421
Corporate debt securities	1,042	1	(9)	1,034
Other debt securities	81	—	—	81
<b>Total</b>	<b>\$ 1,546</b>	<b>\$ 1</b>	<b>\$ (11)</b>	<b>\$ 1,536</b>

AbbVie had no other-than-temporary impairments as of September 30, 2019. Net realized gains and losses were insignificant for both the three and nine months ended September 30, 2019 and 2018.

## Concentrations of Risk

Of total net accounts receivable, three U.S. wholesalers accounted for 68% as of September 30, 2019 and 63% as of December 31, 2018, and substantially all of AbbVie's net revenues in the United States were to these three wholesalers.

HUMIRA (adalimumab) is AbbVie's single largest product and accounted for approximately 58% of AbbVie's total net revenues for the nine months ended September 30, 2019 and 61% for the nine months ended September 30, 2018.

## Debt and Credit Facilities

In September 2019, the company issued €1.4 billion aggregate principal amount of unsecured senior Euro notes, consisting of €750 million aggregate principal amount of 0.75% senior notes due 2027 and €650 million aggregate principal amount of 1.25% senior notes due 2031. These senior notes rank equally with all other unsecured and unsubordinated indebtedness of the company. AbbVie may redeem the senior notes prior to maturity at a redemption price equal to the principal amount of the senior notes redeemed plus a make-whole premium and may redeem the senior notes at par between one and three months prior to maturity. In connection with the offering, debt issuance costs incurred totaled \$9 million and debt discounts totaled \$5 million and are being amortized over the respective terms of the notes to interest expense, net in the condensed consolidated statements of earnings. In October 2019, the company used the proceeds to redeem €1.4 billion aggregate principal amount of 0.38% senior Euro notes that were due to mature in November 2019.

## Short-Term Borrowings

Short-term borrowings included commercial paper borrowings of \$699 million as of December 31, 2018. There were no commercial paper borrowings outstanding as of September 30, 2019. The weighted-average interest rate on commercial paper borrowings was 2.5% for the nine months ended September 30, 2019 and 1.9% for the nine months ended September 30, 2018.

In March 2019, AbbVie repaid its \$3.0 billion 364-day term loan credit agreement that was scheduled to mature in June 2019.

In August 2019, AbbVie entered into an amended and restated \$4.0 billion five-year revolving credit facility that matures in August 2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants, all of which the company was in compliance with as of September 30, 2019. No amounts were outstanding under the company's credit facilities as of September 30, 2019 and December 31, 2018.

In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a 364-day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement. See Note 4 for additional information.

## Note 10 Post-Employment Benefits

The following table summarizes net periodic benefit cost relating to the company's defined benefit and other post-employment plans:

(in millions)	Defined benefit plans				Other post-employment plans			
	Three months ended September 30,		Nine months ended September 30,		Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018	2019	2018	2019	2018
Service cost	\$ 67	\$ 70	\$ 202	\$ 214	\$ 6	\$ 7	\$ 19	\$ 20
Interest cost	64	57	194	171	6	6	21	18
Expected return on plan assets	(118)	(109)	(356)	(330)	—	—	—	—
Amortization of actuarial losses and prior service cost	27	38	82	114	1	—	1	1
Net periodic benefit cost	\$ 40	\$ 56	\$ 122	\$ 169	\$ 13	\$ 13	\$ 41	\$ 39

The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.

## Note 11 Equity

### Stock-Based Compensation

Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:

(in millions)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
Cost of products sold	\$ 4	\$ 7	\$ 24	\$ 23
Research and development	31	32	136	139
Selling, general and administrative	40	36	191	189
Pre-tax compensation expense	75	75	351	351
Tax benefit	15	13	64	61
After-tax compensation expense	\$ 60	\$ 62	\$ 287	\$ 290

### Stock Options

During the nine months ended September 30, 2019, primarily in connection with the company's annual grant, AbbVie granted 1.0 million stock options with a weighted-average grant-date fair value of \$12.54. As of September 30, 2019, \$7 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.

### RSUs and Performance Shares

During the nine months ended September 30, 2019, primarily in connection with the company's annual grant, AbbVie granted 5.5 million RSUs and performance shares with a weighted-average grant-date fair value of \$78.55. As of September 30, 2019, \$365 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.

### Cash Dividends

The following table summarizes quarterly cash dividends declared during 2019 and 2018:

2019			2018		
Date Declared	Payment Date	Dividend Per Share	Date Declared	Payment Date	Dividend Per Share
11/01/19	02/14/20	\$ 1.18	11/02/18	02/15/19	\$ 1.07
09/06/19	11/15/19	\$ 1.07	09/07/18	11/15/18	\$ 0.96
06/20/19	08/15/19	\$ 1.07	06/14/18	08/15/18	\$ 0.96
02/21/19	05/15/19	\$ 1.07	02/15/18	05/15/18	\$ 0.96

## Stock Repurchase Program

The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under these programs are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.

AbbVie repurchased 4 million shares for \$300 million during the nine months ended September 30, 2019 and 94 million shares for \$9.8 billion during the nine months ended September 30, 2018. AbbVie's remaining stock repurchase authorization was approximately \$4.0 billion as of September 30, 2019.

## Accumulated Other Comprehensive Loss

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2019:

(in millions)	Foreign currency translation adjustments	Net investment hedging activities	Pension and post-employment benefits	Marketable security activities	Cash flow hedging activities	Total
Balance as of December 31, 2018	\$ (830)	\$ (65)	\$ (1,722)	\$ (10)	\$ 147	\$ (2,480)
Other comprehensive income (loss) before reclassifications	(288)	199	12	12	77	12
Net losses (gains) reclassified from accumulated other comprehensive loss	—	(15)	66	(2)	(109)	(60)
Net current-period other comprehensive income (loss)	(288)	184	78	10	(32)	(48)
Balance as of September 30, 2019	\$ (1,118)	\$ 119	\$ (1,644)	\$ —	\$ 115	\$ (2,528)

Other comprehensive loss for the nine months ended September 30, 2019 included foreign currency translation adjustments totaling a loss of \$288 million, which was principally due to the weakening of the Euro in the nine months ended September 30, 2019 on the translation of the company's assets denominated in the Euro.

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2018:

(in millions)	Foreign currency translation adjustments	Net investment hedging activities	Pension and post-employment benefits	Marketable security activities	Cash flow hedging activities	Total
Balance as of December 31, 2017	\$ (439)	\$ (203)	\$ (1,919)	\$ —	\$ (166)	\$ (2,727)
Other comprehensive income (loss) before reclassifications	(250)	73	7	(6)	110	(66)
Net losses reclassified from accumulated other comprehensive loss	—	—	92	4	138	234
Net current-period other comprehensive income (loss)	(250)	73	99	(2)	248	168
Balance as of September 30, 2018	\$ (689)	\$ (130)	\$ (1,820)	\$ (2)	\$ 82	\$ (2,559)

Other comprehensive income for the nine months ended September 30, 2018 included foreign currency translation adjustments totaling a loss of \$250 million, which was principally due to the weakening of the Euro in the nine months ended September 30, 2018 on the translation of the company's assets denominated in the Euro.

The following table presents the impact on AbbVie's condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:

(in millions) (brackets denote gains)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
<b>Pension and post-employment benefits</b>				
Amortization of actuarial losses and other <sup>(a)</sup>	\$ 28	\$ 38	\$ 83	\$ 115
Tax benefit	(5)	(8)	(17)	(23)
Total reclassifications, net of tax	\$ 23	\$ 30	\$ 66	\$ 92
<b>Cash flow hedging activities</b>				
Losses (gains) on foreign currency forward exchange contracts <sup>(b)</sup>	\$ (42)	\$ 54	\$ (119)	\$ 144
Tax expense (benefit)	3	—	10	(6)
Total reclassifications, net of tax	\$ (39)	\$ 54	\$ (109)	\$ 138
<b>Net investment hedging activities</b>				
Gains on derivative amount excluded from effectiveness testing <sup>(c)</sup>	\$ (10)	\$ —	\$ (19)	\$ —
Tax expense	2	—	4	—
Total reclassifications, net of tax	\$ (8)	\$ —	\$ (15)	\$ —

(a) Amounts are included in the computation of net periodic benefit cost (see Note 10).

(b) Amounts are included in cost of products sold (see Note 9).

(c) Amounts are included in interest expense, net (see Note 9).

## Note 12 Income Taxes

The effective tax rate was 6% for the three months and 5% for the nine months ended September 30, 2019 and 1% for the three and nine months ended September 30, 2018. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and nine months ended September 30, 2019 over the prior year was principally due to the beneficial impact of the timing of provisions of the Act related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year.

Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company's gross unrecognized tax benefits balance may change within the next twelve months by up to \$193 million.

## Note 13 Legal Proceedings and Contingencies

AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately \$325 million as of September 30, 2019 and \$350 million as of December 31, 2018. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie's consolidated financial position, results of operations or cash flows.

Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.

Four lawsuits against Unimed Pharmaceuticals, LLC, Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as *In re: AndroGel Antitrust Litigation*, MDL No. 2084. These cases, brought by direct AndroGel purchasers, generally allege Solvay's 2006 patent litigation settlement agreements and related agreements with three generic companies violate federal antitrust laws. Plaintiffs seek monetary damages and attorneys' fees.

In September 2014, the FTC filed a lawsuit, *FTC v. AbbVie Inc., et al.*, against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that the 2011 patent litigation with two generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC's settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of \$448 million, plus prejudgment interest. The court denied the FTC's request for injunctive relief. AbbVie is appealing the court's liability and disgorgement rulings and, based on an assessment of the merits of that appeal, no liability has been accrued for this matter. The FTC is also appealing aspects of the court's trial ruling and the dismissal of its settlement-related claim. In July 2018, a purported class action was filed in the United States District Court for the Eastern District of Pennsylvania on behalf of direct AndroGel purchasers based on the trial court's ruling in the FTC's case. In September 2019, two individual direct AndroGel purchasers substituted in as the plaintiffs in that lawsuit and withdrew the class allegations. That case, now pending as *Rochester Drug Co-Operative, Inc., et al. v. AbbVie Inc., et al.*, is stayed pending the appeals in the FTC's case.

In August 2019, direct purchasers of AndroGel filed a lawsuit, *King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.*, against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, making allegations similar to those in *In re: AndroGel Antitrust Litigation (No. II)*, MDL No. 2084 (above) and *FTC v. AbbVie Inc.* (above).

Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as *In re: Niaspan Antitrust Litigation*, MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In October 2016, the Orange County, California District Attorney's Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys' fees. In May 2018, the California Court of Appeal ruled that the District Attorney's Office may not bring monetary claims beyond the scope of Orange County, which the District Attorney's Office is appealing.

In January and February 2019, two shareholder derivative lawsuits, *Brown v. Gonzalez, et al.*, and *Elfers v. Gonzalez, et al.*, were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached their fiduciary duties in connection with HUMIRA patient and reimbursement support services and other services and items of value, as alleged in the *State of California* case discussed below. The lawsuits were consolidated and, on August 19, 2019, the court granted the plaintiffs' voluntary dismissal motion.

Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect HUMIRA purchasers, alleging that AbbVie's settlements with biosimilar manufacturers and AbbVie's HUMIRA patent portfolio violate state and federal antitrust laws. The court consolidated these lawsuits as *In re: Humira (Adalimumab) Antitrust Litigation*.

In November 2014, a putative class action lawsuit, *Medical Mutual of Ohio v. AbbVie Inc., et al.*, was filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insurance companies, health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act and state consumer fraud and deceptive trade practices laws. The complaint seeks monetary damages and injunctive relief. In July 2018, the court denied the plaintiff's motion for

class certification. In February 2019, the court granted the defendants' summary judgment motion, which the plaintiff appealed to the United States Court of Appeals for the Seventh Circuit.

In July 2019, the New Mexico Attorney General filed a lawsuit, *State of New Mexico ex rel. Balderas v. AbbVie Inc., et al.*, in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico's Unfair Practices Act.

In September 2018, the Commissioner of the California Department of Insurance intervened in a *qui tam* lawsuit, *State of California and Lazaro Suarez v. AbbVie Inc., et al.*, brought under the California Insurance Frauds Prevention Act, in California Superior Court for Alameda County. The Department of Insurance's complaint alleges that, through patient and reimbursement support services and other services and items of value provided in connection with HUMIRA, AbbVie caused the submission of fraudulent commercial insurance claims for HUMIRA in violation of the California statute. The complaint seeks injunctive relief, an assessment of up to three times the amount of the claims at issue, and civil penalties. In addition, a federal securities lawsuit (*Holwill v. AbbVie Inc., et al.*) is pending in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for HUMIRA sales growth in financial filings between 2013 and 2017 were misleading because they omitted the conduct alleged in the Department of Insurance's complaint.

In November 2014, five individuals filed a putative class action lawsuit, *Rubinstein, et al. v. Gonzalez, et al.*, on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire. In October 2019, the court granted final approval to the parties' class settlement agreement.

In June 2016, a lawsuit, *Elliott Associates, L.P., et al. v. AbbVie Inc.*, was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages.

Product liability cases were filed in which plaintiffs generally allege that AbbVie and other manufacturers of TRTs did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately 3,900 claims against AbbVie are consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as *In re: Testosterone Replacement Therapy Products Liability Litigation*, MDL No. 2545. Approximately 200 claims against AbbVie are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. In November 2018, AbbVie entered into a Master Settlement Agreement with the Plaintiffs' Steering Committee in the MDL encompassing existing claims in all courts. All proceedings in pending cases are effectively stayed during the settlement administration process.

Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately 150 cases are pending in the United States District Court for the Southern District of Illinois, and approximately seven others are pending in various federal and state courts. Plaintiffs generally seek compensatory and punitive damages. Approximately ninety percent of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice.

Beginning in May 2016, the Patent Trial & Appeal Board of the U.S. Patent & Trademark Office (PTO) instituted five inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to three AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie's appeal of the decisions is pending in the Court of Appeals for the Federal Circuit.

In March 2017, AbbVie filed a lawsuit, *AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd.*, in the United States District Court for the Northern District of California against Novartis Vaccines and Grifols Worldwide seeking a declaratory judgment that 11 HCV-related patents licensed to AbbVie in 2002 are invalid.

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibuprofen capsules (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In February 2018, cases were filed in the United States District Court for the District of Delaware against the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited; Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Sandoz Inc., and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendant's

proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in these suits.

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In a case filed in the United States District Court for the District of Delaware in March 2019, Pharmacyclics alleges that Alvogen Pine Brook LLC's and Natco Pharma Ltd.'s proposed generic ibrutinib tablet product infringes certain Pharmacyclics patents. Pharmacyclics seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in this suit.

## Note 14 Segment Information

AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:

(in millions)		Three months ended September 30,		Nine months ended September 30,	
		2019	2018	2019	2018
<b>Immunology</b>					
HUMIRA	United States	\$ 3,887	\$ 3,546	\$ 10,895	\$ 10,070
	International	1,049	1,578	3,357	4,948
	Total	\$ 4,936	\$ 5,124	\$ 14,252	\$ 15,018
SKYRIZI	United States	\$ 76	\$ —	\$ 118	\$ —
	International	15	—	21	—
	Total	\$ 91	\$ —	\$ 139	\$ —
RINVOQ	United States	\$ 14	\$ —	\$ 14	\$ —
<b>Hematologic Oncology</b>					
IMBRUVICA	United States	\$ 1,042	\$ 812	\$ 2,757	\$ 2,129
	Collaboration revenues	215	160	621	455
	Total	\$ 1,257	\$ 972	\$ 3,378	\$ 2,584
VENCLEXTA	United States	\$ 142	\$ 69	\$ 364	\$ 157
	International	79	27	177	63
	Total	\$ 221	\$ 96	\$ 541	\$ 220
<b>HCV</b>					
MAVYRET	United States	\$ 368	\$ 444	\$ 1,167	\$ 1,206
	International	327	395	1,098	1,413
	Total	\$ 695	\$ 839	\$ 2,265	\$ 2,619
VIEKIRA	United States	\$ —	\$ —	\$ —	\$ 3
	International	3	23	32	132
	Total	\$ 3	\$ 23	\$ 32	\$ 135
<b>Other Key Products</b>					
Creon	United States	\$ 265	\$ 239	\$ 749	\$ 667
Lupron	United States	\$ 187	\$ 173	\$ 546	\$ 530
	International	43	41	122	126
	Total	\$ 230	\$ 214	\$ 668	\$ 656
Synthroid	United States	\$ 197	\$ 192	\$ 582	\$ 567
Synagis	International	\$ 132	\$ 97	\$ 457	\$ 462
Duodopa	United States	\$ 26	\$ 19	\$ 72	\$ 57
	International	91	87	271	260
	Total	\$ 117	\$ 106	\$ 343	\$ 317
Sevoflurane	United States	\$ 18	\$ 18	\$ 53	\$ 54
	International	66	68	214	251
	Total	\$ 84	\$ 86	\$ 267	\$ 305
Kaletra	United States	\$ 7	\$ 16	\$ 30	\$ 42
	International	67	72	199	210
	Total	\$ 74	\$ 88	\$ 229	\$ 252
AndroGel	United States	\$ 53	\$ 135	\$ 149	\$ 393
ORILISSA	United States	\$ 27	\$ 3	\$ 58	\$ 3
	International	—	—	1	—
	Total	\$ 27	\$ 3	\$ 59	\$ 3
All other		\$ 83	\$ 22	\$ 438	\$ 250
Total net revenues		\$ 8,479	\$ 8,236	\$ 24,562	\$ 24,448

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

---

The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of September 30, 2019 and December 31, 2018 and the results of operations for the three and nine months ended September 30, 2019 and 2018. This commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes appearing in Item 1, "Financial Statements and Supplementary Data."

### EXECUTIVE OVERVIEW

#### Company Overview

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories (Abbott). AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.

AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies and patients. Outside the United States, AbbVie sells products primarily to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies. AbbVie has approximately 30,000 employees. AbbVie operates in one business segment—pharmaceutical products.

On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan). See Note 4 to the condensed consolidated financial statements for additional information on the proposed acquisition.

#### 2019 Strategic Objectives

AbbVie's mission is to be an innovation-driven, patient-focused specialty biopharmaceutical company capable of achieving top-tier financial performance through outstanding execution and a consistent stream of innovative new medicines. AbbVie intends to continue to advance its mission in a number of ways, including: (i) growing revenues by diversifying revenue streams, driving late-stage pipeline assets to the market and ensuring strong commercial execution of new product launches; (ii) continued investment and expansion in its pipeline in support of opportunities in immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health as well as continued investment in key on-market products; (iii) expanding operating margins; and (iv) returning cash to shareholders via dividends and share repurchases. In addition, AbbVie anticipates several regulatory submissions and key data readouts from key clinical trials in the next twelve months.

#### Financial Results

The company's financial performance for the nine months ended September 30, 2019 included delivering worldwide net revenues of \$24.6 billion, operating earnings of \$9.0 billion, diluted earnings per share of \$3.41 and cash flows from operations of \$10.0 billion. Worldwide net revenues grew by 2% on a constant currency basis, primarily driven by revenue growth related to IMBRUVICA and VENCLEXTA as well as the continued strength of HUMIRA in the U.S. and newly launched immunology assets SKYRIZI and RINVOQ, offset by international HUMIRA biosimilar competition.

Diluted earnings per share was \$3.41 for the nine months ended September 30, 2019 and included the following after-tax costs: (i) \$2.7 billion for the change in fair value of contingent consideration liabilities; (ii) \$962 million related to the amortization of intangible assets; (iii) a Stemcentrx-related impairment charge of \$823 million net of the related fair value adjustment to contingent consideration liabilities; (iv) \$241 million for acquired in-process research and development (IPR&D); (v) \$155 million of expenses related to the proposed Allergan acquisition; (vi) \$153 million of restructuring charges; and (vii) \$95 million for milestone payments. These costs were partially offset by an after-tax benefit of \$267 million due to the favorable resolution of various tax positions.

Additionally, financial results reflected continued funding to support all stages of AbbVie's emerging pipeline assets and continued investment in AbbVie's on-market brands.

In November 2019, the company announced that its board of directors declared an increase in the company's quarterly cash dividend from \$1.07 per share to \$1.18 per share beginning with the dividend payable in February 2019. This reflects an increase of approximately 10.3% over the previous quarterly rate.

In addition to these financial results, AbbVie continued to advance and augment its pipeline as further described below under the heading "Research and Development."

## Research and Development

Research and innovation are the cornerstones of AbbVie's business as a global biopharmaceutical company. AbbVie's long-term success depends to a great extent on its ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.

AbbVie's pipeline currently includes approximately 50 compounds or indications in clinical development individually or under collaboration or license agreements and is focused on such important medical specialties as immunology, oncology and neuroscience along with targeted investments in cystic fibrosis and women's health. Of these programs, approximately 30 are in mid- and late-stage development.

The following sections summarize transitions of significant programs from Phase 2 development to Phase 3 development as well as developments in significant Phase 3 and registration programs. AbbVie expects multiple Phase 2 programs to transition into Phase 3 programs in the next twelve months.

### Significant Programs and Developments

#### Immunology

##### RINVOQ

- In February 2019, the U.S. Food and Drug Administration (FDA) accepted for priority review AbbVie's New Drug Application (NDA) for upadacitinib, an investigational oral JAK1-selective inhibitor, for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA).
- In February 2019, AbbVie initiated a Phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell arteritis.
- In August 2019, the FDA approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.
- In October 2019, AbbVie announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for RINVOQ for the treatment of adults with moderate to severe active RA.
- In October 2019, AbbVie announced top-line results from its first Phase 3 clinical trial of RINVOQ in adult patients with active psoriatic arthritis. Results from the SELECT-PsA 2 study, which evaluated RINVOQ versus placebo in patients who did not adequately respond to treatment with one or more biologic DMARDs, showed that both doses of RINVOQ (15 mg and 30 mg) met the primary endpoint of ACR20 response at week 12. Key secondary endpoints were also achieved and included HAQ-DI, PASI75, minimal disease activity, ACR50 and ACR70. The safety profile was consistent with that of previous studies across indications, with no new safety signals detected.

##### SKYRIZI

- In March 2019, AbbVie initiated two Phase 3 clinical trials to evaluate the efficacy and safety of risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in subjects with psoriatic arthritis.
- In April 2019, the FDA approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- In April 2019, the European Commission granted marketing authorization for SKYRIZI for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

#### IMBRUVICA

- In January 2019, the FDA approved IMBRUVICA, in combination with GAZYVA (obinutuzumab), for adult patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- In June 2019, AbbVie announced results from the Phase 3 CLL12 trial, evaluating IMBRUVICA in patients with previously untreated CLL, which demonstrated that IMBRUVICA significantly improved event- and progression-free survival.

#### VENCLEXTA

- In March 2019, AbbVie announced that the FDA placed a partial clinical hold on all clinical trials evaluating VENCLEXTA for the investigational treatment of multiple myeloma (MM). The partial clinical hold followed a review of data from the ongoing Phase 3 BELLINI trial, a study in relapsed/refractory MM, in which a higher proportion of deaths was observed in the VENCLEXTA arm compared to the control arm of the trial. In June 2019, AbbVie announced that the FDA lifted the partial clinical hold placed on the Phase 3 CANOVA trial, evaluating VENCLEXTA for the investigational treatment of relapsed/refractory MM positive for the translocation (11;14) abnormality, based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria. This action does not impact any of the approved indications for VENCLEXTA, such as CLL or acute myeloid leukemia (AML).
- In May 2019, the FDA approved VENCLEXTA, in combination with obinutuzumab, for adult patients with previously untreated CLL/SLL. The approval was based on data from the Phase 3 CLL14 trial, evaluating the efficacy and safety of VENCLEXTA plus obinutuzumab versus obinutuzumab plus chlorambucil in previously untreated patients with CLL, which demonstrated that VENCLEXTA plus obinutuzumab prolonged progression-free survival and achieved higher rates of complete response and minimal residual disease-negativity compared to commonly used standard of care obinutuzumab plus chlorambucil.

#### Depatux-M

- In May 2019, AbbVie announced the decision to discontinue the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma, whose tumors have EGFR (epidermal growth factor receptor) amplification, at an interim analysis. An Independent Data Monitoring Committee recommended stopping enrollment in INTELLANCE-1 due to lack of survival benefit for patients receiving Depatux-M compared with placebo when added to the standard regimen of radiation and temozolomide. Enrollment has been halted in all ongoing Depatux-M studies.

#### Veliparib

- In July 2019, AbbVie announced that top-line results from the Phase 3 BROCADE3 study evaluating veliparib, an investigational, oral poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, in combination with carboplatin and paclitaxel met its primary endpoint of progression-free survival in patients with HER2 negative germline BRCA-mutated advanced breast cancer.
- In July 2019, AbbVie announced that top-line results from the Phase 3 VELIA study, conducted in collaboration with the GOG Foundation, Inc., evaluating veliparib with carboplatin and paclitaxel followed by veliparib maintenance therapy met its primary endpoint of progression-free survival in patients with newly diagnosed ovarian cancer, regardless of biomarker status.

#### Rova-T

- In August 2019, AbbVie announced the decision to terminate the MERU trial, a Phase 3 study evaluating rovalpituzumab tesirine (Rova-T) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC). An Independent Data Monitoring Committee recommended terminating the study after results demonstrated no survival benefit at a pre-planned interim analysis for patients receiving Rova-T as compared with placebo. With the closing of the MERU trial, AbbVie announced the termination of the Rova-T research and development program.

### *Virology/Liver Disease*

- In August 2019, the European Commission granted marketing authorization for MAVIRET (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT)1, 2, 4, 5 and 6 infection. An analysis from the same clinical trial evaluating MAVIRET as an 8-week, once-daily treatment option for treatment-naïve, compensated cirrhotic, GT3 HCV patients is ongoing.
- In September 2019, the FDA approved MAVYRET (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic HCV patients across all genotypes (GT1-6).

### *Neuroscience*

- In May 2019, AbbVie initiated a Phase 3 clinical trial to evaluate the safety and tolerability of ABBV-951, a subcutaneous levodopa/carbidopa delivery system, in subjects with Parkinson's disease.
- In July 2019, AbbVie announced the decision to discontinue the Phase 2 ARISE study evaluating ABBV-8E12, an investigational anti-tau antibody, in patients with progressive supranuclear palsy, after an Independent Data Monitoring Committee recommended stopping the trial for futility after the trial showed that ABBV-8E12 did not provide efficacy.

### *Other*

- In July 2019, AbbVie submitted an NDA to the FDA for elagolix in combination with estradiol/norethindrone acetate (E2/NETA) daily add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids.

For a more comprehensive discussion of AbbVie's products and pipeline, see the company's Annual Report on Form 10-K for the year ended December 31, 2018.

## RESULTS OF OPERATIONS

### Net Revenues

The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year's foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company's operations and can facilitate analysis of the company's results of operations, particularly in evaluating performance from one period to another.

(dollars in millions)	Three months ended September 30,		Percent change		Nine months ended September 30,		Percent change	
	2019	2018	At actual currency rates	At constant currency rates	2019	2018	At actual currency rates	At constant currency rates
	United States	\$ 6,244	\$ 5,597	11.6 %	11.6 %	\$ 17,478	\$ 15,836	10.4 %
International	2,235	2,639	(15.3)%	(13.7)%	7,084	8,612	(17.7)%	(14.1)%
Net revenues	\$ 8,479	\$ 8,236	3.0 %	3.5 %	\$ 24,562	\$ 24,448	0.5 %	1.8 %

The following table details AbbVie's worldwide net revenues:

(dollars in millions)		Three months ended September 30,		Percent change		Nine months ended September 30,		Percent change		
		2019	2018	At actual currency rates	At constant currency rates	2019	2018	At actual currency rates	At constant currency rates	
<b>Immunology</b>										
HUMIRA	United States	\$ 3,887	\$ 3,546	9.6 %	9.6 %	\$ 10,895	\$ 10,070	8.2 %	8.2 %	
	International	1,049	1,578	(33.5)%	(31.8)%	3,357	4,948	(32.1)%	(28.5)%	
	Total	\$ 4,936	\$ 5,124	(3.7)%	(3.2)%	\$ 14,252	\$ 15,018	(5.1)%	(3.9)%	
SKYRIZI	United States	\$ 76	\$ —	n/m	n/m	\$ 118	\$ —	n/m	n/m	
	International	15	—	n/m	n/m	21	—	n/m	n/m	
	Total	\$ 91	\$ —	n/m	n/m	\$ 139	\$ —	n/m	n/m	
RINVOQ	United States	\$ 14	\$ —	n/m	n/m	\$ 14	\$ —	n/m	n/m	
<b>Hematologic Oncology</b>										
IMBRUVICA	United States	\$ 1,042	\$ 812	28.3 %	28.3 %	\$ 2,757	\$ 2,129	29.5 %	29.5 %	
	Collaboration revenues	215	160	34.5 %	34.5 %	621	455	36.5 %	36.5 %	
	Total	\$ 1,257	\$ 972	29.3 %	29.3 %	\$ 3,378	\$ 2,584	30.7 %	30.7 %	
VENCLEXTA	United States	\$ 142	\$ 69	>100.0%	>100.0%	\$ 364	\$ 157	>100.0%	>100.0%	
	International	79	27	>100.0%	>100.0%	177	63	>100.0%	>100.0%	
	Total	\$ 221	\$ 96	>100.0%	>100.0%	\$ 541	\$ 220	>100.0%	>100.0%	
<b>HCV</b>										
MAVYRET	United States	\$ 368	\$ 444	(17.0)%	(17.0)%	\$ 1,167	\$ 1,206	(3.2)%	(3.2)%	
	International	327	395	(17.2)%	(16.4)%	1,098	1,413	(22.3)%	(19.3)%	
	Total	\$ 695	\$ 839	(17.1)%	(16.7)%	\$ 2,265	\$ 2,619	(13.5)%	(11.9)%	
VIEKIRA	United States	\$ —	\$ —	n/m	n/m	\$ —	\$ 3	(100.0)%	(100.0)%	
	International	3	23	(88.1)%	(88.6)%	32	132	(75.4)%	(72.5)%	
	Total	\$ 3	\$ 23	(88.0)%	(88.5)%	\$ 32	\$ 135	(76.6)%	(73.7)%	
<b>Other Key Products</b>										
Creon	United States	\$ 265	\$ 239	11.2 %	11.2 %	\$ 749	\$ 667	12.4 %	12.4 %	
Lupron	United States	\$ 187	\$ 173	8.6 %	8.6 %	\$ 546	\$ 530	3.1 %	3.1 %	
	International	43	41	3.7 %	6.2 %	122	126	(3.3)%	2.7 %	
	Total	\$ 230	\$ 214	7.7 %	8.2 %	\$ 668	\$ 656	1.9 %	3.1 %	
Synthroid	United States	\$ 197	\$ 192	2.3 %	2.3 %	\$ 582	\$ 567	2.6 %	2.6 %	
Synagis	International	\$ 132	\$ 97	36.2 %	35.4 %	\$ 457	\$ 462	(1.0)%	2.2 %	
Duodopa	United States	\$ 26	\$ 19	36.4 %	36.4 %	\$ 72	\$ 57	25.5 %	25.5 %	
	International	91	87	5.8 %	9.6 %	271	260	4.5 %	10.7 %	
	Total	\$ 117	\$ 106	11.3 %	14.4 %	\$ 343	\$ 317	8.3 %	13.4 %	
Sevoflurane	United States	\$ 18	\$ 18	(2.5)%	(2.5)%	\$ 53	\$ 54	(2.2)%	(2.2)%	
	International	66	68	(3.1)%	(0.5)%	214	251	(14.8)%	(9.8)%	
	Total	\$ 84	\$ 86	(3.0)%	(0.9)%	\$ 267	\$ 305	(12.5)%	(8.4)%	
Kaletra	United States	\$ 7	\$ 16	(48.7)%	(48.7)%	\$ 30	\$ 42	(27.7)%	(27.7)%	
	International	67	72	(7.2)%	(6.1)%	199	210	(5.1)%	(1.0)%	
	Total	\$ 74	\$ 88	(14.8)%	(13.9)%	\$ 229	\$ 252	(8.9)%	(5.5)%	
AndroGel	United States	\$ 53	\$ 135	(61.1)%	(61.1)%	\$ 149	\$ 393	(62.2)%	(62.2)%	
ORILISSA	United States	\$ 27	\$ 3	>100.0%	>100.0%	\$ 58	\$ 3	>100.0%	>100.0%	
	International	—	—	n/m	n/m	1	—	n/m	n/m	
	Total	\$ 27	\$ 3	>100.0%	>100.0%	\$ 59	\$ 3	>100%	>100%	
All other		\$ 83	\$ 22	>100.0%	>100.0%	\$ 438	\$ 250	74.5 %	81.3 %	
<b>Total net revenues</b>		<b>\$ 8,479</b>	<b>\$ 8,236</b>	<b>3.0 %</b>	<b>3.5 %</b>	<b>\$ 24,562</b>	<b>\$ 24,448</b>	<b>0.5 %</b>	<b>1.8 %</b>	

n/m – Not meaningful

The following discussion and analysis of AbbVie's net revenues by product is presented on a constant currency basis.

Global HUMIRA sales decreased 3% for the three months and 4% for the nine months ended September 30, 2019 primarily as a result of direct biosimilar competition in certain international markets, partially offset by market growth across therapeutic categories. In the United States, HUMIRA sales increased 10% for the three months and 8% for the nine months ended September

30, 2019 driven by market growth across all indications. Internationally, HUMIRA sales decreased 32% for the three months and 29% for the nine months ended September 30, 2019 primarily driven by direct biosimilar competition in certain international markets following the expiration of the European Union composition of matter patent for adalimumab in October 2018. Biosimilar competition for HUMIRA is not expected in the United States until 2023. AbbVie continues to pursue strategies intended to further differentiate HUMIRA from competing products and add to the sustainability of HUMIRA.

Net revenues for SKYRIZI were \$91 million for the three months and \$139 million for the nine months ended September 30, 2019 following the April 2019 regulatory approvals for the treatment of moderate to severe plaque psoriasis.

Net revenues for RINVOQ were \$14 million for the three and nine months ended September 30, 2019 following the August 2019 FDA approval for the treatment of moderate to severe rheumatoid arthritis.

Net revenues for IMBRUVICA represent product sales in the United States and collaboration revenues outside of the United States related to AbbVie's 50% share of IMBRUVICA profit. AbbVie's global IMBRUVICA revenues increased 29% for the three months and 31% for the nine months ended September 30, 2019 as a result of continued penetration of IMBRUVICA for patients with CLL as well as favorable pricing.

Net revenues for VENCLEXTA increased by more than 100% for the three and nine months ended September 30, 2019 primarily due to market share gains following additional regulatory approvals of VENCLEXTA for the treatment of patients with relapsed/refractory CLL and first-line AML in 2018 and first-line CLL in 2019.

Global MAVYRET sales decreased by 17% for the three months and 12% for the nine months ended September 30, 2019 primarily driven by lower patient volumes in certain international markets and competitive dynamics in the U.S.

Net revenues for Creon increased 11% for the three months and 12% for the nine months ended September 30, 2019 primarily driven by continued market growth. Creon maintains market leadership in the pancreatic enzyme market.

Net revenues for Duodopa increased 14% for the three months and 13% for the nine months ended September 30, 2019 primarily driven by increased market penetration.

## Gross Margin

(dollars in millions)	Three months ended September 30,			Nine months ended September 30,		
	2019	2018	% change	2019	2018	% change
Gross margin	\$ 6,559	\$ 6,401	2%	\$ 19,129	\$ 18,752	2%
as a % of net revenues	77%	78%		78%	77%	

Gross margin as a percentage of net revenues decreased for the three months and increased for the nine months ended September 30, 2019 compared to the prior year. Gross margin percentage for the three months ended September 30, 2019 was unfavorably impacted by higher intangible asset amortization and the IMBRUVICA profit sharing arrangement offset by the expiration of HUMIRA royalties. Gross margin percentage for the nine months ended September 30, 2019 was favorably impacted by the expiration of HUMIRA royalties offset by higher intangible asset amortization and the IMBRUVICA profit sharing arrangement.

## Selling, General and Administrative

(dollars in millions)	Three months ended September 30,			Nine months ended September 30,		
	2019	2018	% change	2019	2018	% change
Selling, general and administrative	\$ 1,657	\$ 1,919	(14)%	\$ 4,991	\$ 5,470	(9)%
as a % of net revenues	20%	23%		20%	22%	

Selling, general and administrative (SG&A) expenses as a percentage of net revenues decreased for the three and nine months ended September 30, 2019 compared to the prior year. SG&A expense for the three and nine months ended September 30, 2019 was favorably impacted by litigation reserve charges that decreased by \$221 million for the three months and \$319 million for the nine months ended September 30, 2019, lower charitable contributions to certain U.S. not-for-profit organizations and international

HUMIRA expense reductions. This favorability was partially offset by new product launch expenses and transaction costs associated with the proposed Allergan acquisition of \$26 million for the three months and \$50 million for the nine months ended September 30, 2019. In addition, for the nine months ended September 30, 2019, SG&A expense was unfavorably impacted by restructuring charges.

### Research and Development and Acquired In-Process Research and Development

(dollars in millions)	Three months ended September 30,			Nine months ended September 30,		
	2019	2018	% change	2019	2018	% change
Research and development	\$ 2,285	\$ 1,268	80 %	\$ 4,865	\$ 3,834	27%
as a % of net revenues	27%	15%		20%	16%	
Acquired in-process research and development	\$ —	\$ 55	(100)%	\$ 246	\$ 124	99%

Research and development (R&D) expenses as a percentage of net revenues increased for the three and nine months ended September 30, 2019 compared to the prior year principally due to a \$1.0 billion intangible asset impairment charge which represented the remaining value of the IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to terminate the Rova-T R&D program. See Note 6 to the Condensed Consolidated Financial Statements for additional information regarding the impairment charge. The remaining R&D expenses included continued funding to support all stages of the company's emerging pipeline assets.

Acquired IPR&D expenses reflect upfront payments related to various collaborations. There were no individually significant transactions during both the three and nine months ended September 30, 2019 and 2018.

### Other Operating Expenses

There were no other operating expenses for the three and nine months ended September 30, 2019. Other operating expenses for the nine months ended September 30, 2018 included a \$500 million charge related to the extension of the previously announced collaboration with Calico Life Sciences LLC (Calico) to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer.

### Other Non-Operating Expenses

(in millions)	Three months ended September 30,		Nine months ended September 30,	
	2019	2018	2019	2018
Interest expense	\$ 480	\$ 339	\$ 1,225	\$ 968
Interest income	(60)	(37)	(171)	(143)
Interest expense, net	\$ 420	\$ 302	\$ 1,054	\$ 825
Net foreign exchange loss	\$ 19	\$ 2	\$ 31	\$ 18
Other expense, net	177	94	2,590	411

Interest expense, net increased for the three and nine months ended September 30, 2019 compared to the prior year primarily due to financing related fees incurred in connection with the proposed Allergan acquisition, which totaled \$132 million for the three months and \$139 million for the nine months ended September 30, 2019, as well as the unfavorable impact of higher interest rates on the company's debt obligations.

Other expense, net included charges related to changes in fair value of contingent consideration liabilities of \$180 million for the three months and \$2.7 billion for the nine months ended September 30, 2019 compared to charges of \$95 million for the three months and \$432 million for the nine months ended September 30, 2018. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory/commercial milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors. For the three and nine months ended September 30, 2019, the change in fair value represented higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory

approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis. These changes were partially offset by a \$91 million decrease in the Stemcentrx contingent consideration liability due to the termination of the Rova-T R&D program during the third quarter of 2019. For the three months ended September 30, 2018, the change in fair value represented the passage of time. For the nine months ended September 30, 2018, the change in fair value represented higher estimated future sales and the passage of time partially offset by the effect of rising interest rates.

### Income Tax Expense

The effective tax rate was 6% for the three months and 5% for the nine months ended September 30, 2019 and 1% for the three and nine months ended September 30, 2018. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and nine months ended September 30, 2019 over the prior year was principally due to the beneficial impact of the timing of provisions of the Tax Cuts and Jobs Act (the Act) related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year.

### FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

(in millions)	Nine months ended September 30,	
	2019	2018
Cash flows provided by (used in):		
Operating activities	\$ 10,049	\$ 10,035
Investing activities	1,211	(723)
Financing activities	(7,894)	(10,571)

Operating cash flows for the nine months ended September 30, 2019 were flat compared to the prior year due to improved results of operations resulting from an increase in operating earnings and lower defined benefit plan contributions, offset by higher payments for income taxes. AbbVie's contributions to its defined benefit plans were \$310 million for the nine months ended September 30, 2019 and \$848 million for the nine months ended September 30, 2018.

Investing cash flows for the nine months ended September 30, 2019 included net sales and maturities of investment securities totaling \$2.1 billion resulting from the sale of substantially all of the company's investments in debt securities, payments made for acquisitions and investments of \$476 million and capital expenditures of \$389 million. Investing cash flows for the nine months ended September 30, 2018 included payments made for acquisitions and investments of \$541 million, capital expenditures of \$515 million and net sales and maturities of investment securities totaling \$333 million.

Financing cash flows for the nine months ended September 30, 2019 included the repayment of AbbVie's \$3.0 billion 364-day term loan credit agreement that was scheduled to mature in June 2019. In September 2019, the company issued €1.4 billion aggregate principal amount of unsecured senior Euro notes. In October 2019, the company used the proceeds to redeem €1.4 billion aggregate principal amount of 0.38% senior Euro notes that were due to mature in November 2019.

The company made cash dividend payments of \$4.8 billion for the nine months ended September 30, 2019 and \$4.1 billion for the nine months ended September 30, 2018. The increase in cash dividend payments was driven by an increase in the quarterly dividend rate. On September 6, 2019, the board of directors declared a quarterly cash dividend of \$1.07 per share for stockholders of record at the close of business on October 15, 2019, payable on November 15, 2019. In November 2019, the company announced that its board of directors declared an increase in the company's quarterly cash dividend from \$1.07 per share to \$1.18 per share beginning with the dividend payable in February 2020 to stockholders of record as of January 15, 2020. This reflects an increase of approximately 10.3% over the previous quarterly rate. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie's financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie's debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.

The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. AbbVie repurchased 4 million shares for \$300 million during the nine months ended September 30, 2019 and 94 million shares for \$9.8 billion during the nine months ended September 30, 2018. AbbVie cash-settled \$201 million of its December 2018 open-market purchases in January 2019.

During the nine months ended September 30, 2019, AbbVie made contingent consideration milestone and royalty payments totaling \$179 million following the commercial launch of SKYRIZI in certain geographies. \$120 million of these payments were included in financing cash flows and \$59 million of the payments were included in operating cash flows.

During the nine months ended September 30, 2019 and 2018, the company issued and redeemed commercial paper. The balance of commercial paper outstanding was \$699 million as of December 31, 2018. There were no commercial paper borrowings outstanding as of September 30, 2019. AbbVie may issue additional commercial paper or retire commercial paper to meet liquidity requirements as needed.

During the nine months ended September 30, 2019, AbbVie paid debt issuance costs of \$248 million, primarily related to financing fees associated with the proposed Allergan acquisition.

In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a 364-day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement. See Note 4 to the condensed consolidated financial statements for additional information.

### **Credit Risk**

AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance against accounts receivable when it is probable they will not be collected. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.

### **Credit Facility, Access to Capital and Credit Ratings**

#### *Credit Facility*

In August 2019, AbbVie entered into an amended and restated \$4.0 billion five-year revolving credit facility that matures in August 2024. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At September 30, 2019, the company was in compliance with all its credit facility covenants. Commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facilities as of September 30, 2019 and December 31, 2018.

#### *Access to Capital*

The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or by issuing additional debt. The company's ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company's products or in the solvency of its customers or suppliers, deterioration in the company's key financial ratios or credit ratings or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company's growth objectives.

#### *Credit Ratings*

On June 25, 2019, following the announcement of the proposed acquisition of Allergan, Moody's Investor Service affirmed its Baa2 senior unsecured long-term rating and Prime-2 short-term rating with a stable outlook. S&P Global Ratings revised its ratings outlook to negative from stable and expects to lower the issuer credit rating by one notch to BBB+ from A- and the short-term rating to A-2 from A-1 when the acquisition is complete.

Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company's ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company's outstanding debt.

#### **CRITICAL ACCOUNTING POLICIES**

A summary of the company's significant accounting policies is included in Note 2, "Summary of Significant Accounting Policies" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2018. Significant changes in the company's application of its critical accounting policies include the adoption of a new accounting standard that establishes a new lease accounting framework. See Notes 1 and 8 to the condensed consolidated financial statements for additional information.

#### **FORWARD-LOOKING STATEMENTS**

Some statements in this quarterly report on Form 10-Q may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project," and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2018, which has been filed with the Securities and Exchange Commission. AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

#### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

---

For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2018.

## ITEM 4. CONTROLS AND PROCEDURES

---

### DISCLOSURE CONTROLS AND PROCEDURES

**Evaluation of disclosure controls and procedures.** The Chief Executive Officer, Richard A. Gonzalez, and the Chief Financial Officer, Robert A. Michael, evaluated the effectiveness of AbbVie's disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie's disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Exchange Act is accumulated and communicated to AbbVie's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

### INTERNAL CONTROL OVER FINANCIAL REPORTING

**Changes in internal control over financial reporting.** There were no changes in AbbVie's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, AbbVie's internal control over financial reporting during the quarter ended September 30, 2019.

**Inherent Limitations on Effectiveness of Controls.** AbbVie's management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie's disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.

The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

---

Information pertaining to legal proceedings is provided in Note 13 to the condensed consolidated financial statements and is incorporated by reference herein.

### ITEM 1A. RISK FACTORS

---

There have been no material changes to the risk factors disclosed in AbbVie's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, except for the following:

***The proposed acquisition of Allergan plc ("Allergan") may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.***

Consummation of the acquisition of Allergan by AbbVie is conditioned on, among other things, obtaining necessary governmental and regulatory approvals. If any of the conditions to the acquisition is not satisfied, it could delay or prevent the proposed acquisition from occurring, which could negatively impact AbbVie's share price and future business and financial results. Further, as a condition to their approval of the acquisition, agencies may impose requirements, limitations or costs or require divestitures or place restrictions on the conduct of AbbVie's business after the closing. These requirements, limitations, costs, divestitures or restrictions could jeopardize or delay the consummation of the acquisition or may reduce the anticipated benefits of the transaction. AbbVie will incur increased indebtedness to fund the cash consideration for the acquisition and such indebtedness could adversely affect AbbVie's business, financial condition, or results of operations. In addition, changes in laws and regulations, including Irish legislation implementing a tax increase payable upon completion of the proposed acquisition, could adversely impact AbbVie's post-acquisition financial results. Following the proposed acquisition, AbbVie may not realize the proposed acquisition's intended benefits within the expected timeframe or at all.

### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

---

#### (c) Issuer Purchases of Equity Securities

Period	(a) Total Number of Shares (or Units) Purchased	(b) Average Price Paid per Share (or Unit)	(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 1, 2019 – July 31, 2019	1,281 <sup>(1)</sup>	\$71.19 <sup>(1)</sup>	—	\$3,950,021,071
August 1, 2019 – August 31, 2019	1,290 <sup>(1)</sup>	\$65.06 <sup>(1)</sup>	—	\$3,950,021,071
September 1, 2019 – September 30, 2019	1,245 <sup>(1)</sup>	\$67.27 <sup>(1)</sup>	—	\$3,950,021,071
Total	3,816 <sup>(1)</sup>	\$67.84 <sup>(1)</sup>	—	\$3,950,021,071

1. In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,281 in July; 1,290 in August; and 1,245 in September.

These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.

## ITEM 6. EXHIBITS

---

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

<b>Exhibit No.</b>	<b>Exhibit Description</b>
1.1	*Underwriting Agreement, dated September 17, 2019, among AbbVie Inc. and Morgan Stanley & Co. International plc, HSBC Bank plc and Merrill Lynch International (acting for themselves and as representatives of the several underwriters named therein) (incorporated by reference to Exhibit 1.1 of AbbVie’s Current Report on Form 8-K filed on September 23, 2019).
4.2	*Supplemental Indenture No. 6, dated September 26, 2019, among AbbVie Inc., U.S. Bank National Association, as trustee, transfer agent and registrar, and Elavon Financial Services DAC, UK Branch, as paying agent (incorporated by reference to Exhibit 4.2 of AbbVie’s Current Report on Form 8-K filed on September 26, 2019).
4.3	*Agency Agreement, dated September 26, 2019, among AbbVie Inc., U.S. Bank National Association, as trustee, transfer agent and registrar, and Elavon Financial Services DAC, UK Branch, as paying agent (incorporated by reference to Exhibit 4.3 of AbbVie’s Current Report on Form 8-K filed on September 26, 2019).
10.1	*Amended and Restated Revolving Credit Agreement, dated as of August 27, 2019, among AbbVie, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of AbbVie’s Current Report on Form 8-K filed on August 30, 2019).
10.2	AbbVie Non-Employee Directors' Fee Plan, as amended and restated.**
31.1	Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2	Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed on November 6, 2019, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements.

---

\* Incorporated herein by reference. Commission file number 001-35565.

\*\* Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.



**ABBVIE NON-EMPLOYEE DIRECTORS' FEE PLAN**

(Amended and Restated Effective as of October 17, 2019)

**ABBVIE  
NON-EMPLOYEE DIRECTORS' FEE PLAN**

**SECTION 1.  
PURPOSE**

This AbbVie Non-Employee Directors' Fee Plan (the "Plan") is maintained by AbbVie Inc. (the "Company") to attract and retain as members of its Board of Directors persons who are not full-time employees of the Company or any of its subsidiaries but whose business experience and judgment are valuable assets to the Company and its subsidiaries. The Plan was originally adopted by the Company effective January 1, 2013, and was last amended and restated effective as of May 4, 2018. The terms of the Plan set forth in this document shall be effective as of October 17, 2019 (the "Effective Date").

**SECTION 2.  
DIRECTORS COVERED**

As used in the Plan, the term "Director" means any person serving on the Board of Directors of the Company on the Effective Date or at any time thereafter who is not a full-time employee of the Company or any of its subsidiaries.

**SECTION 3.  
FEES PAYABLE TO DIRECTORS**

3.1 Each Director shall be entitled to a deferred fee of \$110,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position with the Company, excluding the month in which the Director is first elected to such position.

3.2 Lead Director and Executive Committee Chair Fees

(a) A Director who serves as Lead Director for the Board of Directors shall be entitled to a deferred fee of \$50,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

(b) A Director who serves as Chair of the Executive Committee of the Board of Directors shall be entitled to a deferred fee of \$20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

3.3 Audit Committee Fees

(a) A Director who serves as Chair of the Audit Committee of the Board of Directors shall be entitled to a deferred fee of \$25,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

(b) Each Director who serves on the Audit Committee of the Board of Directors (other than the Chair of the Audit Committee) shall be entitled to a deferred fee of \$6,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

3.4 A Director who serves as Chair of the Compensation Committee of the Board of Directors shall be entitled to a deferred fee of \$20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

3.5 A Director who serves as Chair of the Nominations Committee of the Board of Directors shall be entitled to a deferred fee of \$20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

3.6 A Director who serves as Chair of any other Committee created by the Board of Directors shall be entitled to a deferred fee of \$20,000 per year, earned monthly for each calendar month or portion thereof that the Director holds such position, excluding the month in which the Director is first elected to such position.

3.7 A Director's Deferred Fee Account shall be credited with interest annually. The rate of interest credited to deferred fees shall be equal to: (a) the average of the "prime rate" of interest set forth on the Bloomberg Screen BTMM or comparable successor quotation service on the first business day of January and the last business day of each month of the fiscal year; plus (b) two hundred twenty-five (225) basis points. For purposes of this provision, the term "deferred fees" shall include "deferred monthly fees," and "deferred meeting fees," and shall also include any such interest credited thereon.

3.8 For purposes of Sections 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6, the automatic deferral of the fees specified therein shall be subject to a Director's election to receive such fees currently pursuant to Section 4.1 or Section 8.1 of the Plan.

#### SECTION 4. PAYMENT OF DIRECTORS' FEES

4.1 Any Director may, by written notice filed with the Secretary of the Company no later than December 31 in a calendar year, elect to receive current payment of all or any portion of the monthly and meeting fees earned by him in calendar years subsequent to the calendar year in which he files such notice, in which case such fees shall not be deferred but shall be paid quarterly as earned and no interest shall be credited thereon. Such election shall be irrevocable as of December 31 of the year prior to the year in which the fees will be earned.

Notwithstanding the timing requirements described above, an individual who is newly elected as a Director may make the election described above by filing it with the Secretary of the Company within the thirty (30) day period immediately following the date he or she first

becomes a Director eligible to participate in the Plan (and all plans that would be aggregated with the Plan pursuant to Treasury Regulation §1.409A-1(c)(2)(i)), provided that the compensation subject to such election relates solely to services performed after the date of such election and provided, further, that such election shall become irrevocable on the thirtieth day following the date he or she first becomes a Director eligible to participate in the Plan. In no event shall the fees subject to an election under this Section 4.1 be paid later than the last day of the “applicable 2½ month period,” as such term is defined in Treasury Regulation §1.409A-1(b)(4)(i)(A). Any Director who has previously provided notice pursuant to this Section 4.1 may, by written notice filed with the Secretary of the Company no later than December 31 in a calendar year, elect to defer payment of all or a portion of the monthly and meeting fees earned by him in calendar years subsequent to the year in which he files such notice, in which case such fees shall be paid to him in accordance with Section 4.2 below.

4.2 A Director’s deferred fees earned pursuant to the Plan shall commence to be paid on the first day of the calendar month next following the earlier of his death or his attainment of age sixty-five (65) if he is not then serving as a Director, or the termination of his service as a Director if he serves as a Director after the attainment of age sixty-five (65).

4.3 A Director’s deferred fees that have commenced to be payable pursuant to Section 4.2 shall be payable in annual installments in the order in which they shall have been deferred (i.e., the deferred fees and earnings thereon for the earliest year of service as a Director will be paid on the date provided for in Section 4.2, the deferred fees for the next earliest year of service as a Director will be paid on the anniversary of the payment of the first installment, etc.).

4.4 A Director’s deferred fees shall continue to be paid until all deferred fees which he is entitled to receive under the Plan shall have been paid to him (or, in case of his death, to his beneficiary).

4.5 If a Director incurs a termination of service as a Director within two (2) years following the occurrence of a Change in Control (as defined below), the aggregate unpaid balance of such Director’s deferred fees plus all unpaid interest credited thereon shall be paid to such Director in a lump sum within thirty (30) days following the date of such termination of service; provided, however, that if such Change in Control does not constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)), then the aggregate unpaid balance of such Director’s deferred fees shall be paid in accordance with Sections 4.2 and 4.3.

Notwithstanding any other provision of the Plan, if a Director has made the alternative election set forth in Section 8.1, and if such Director incurs a termination of service as a Director within five (5) years following the occurrence of a Change in Control, the aggregate unpaid balance of such Director’s fees deposited to the Director’s Grantor Trust (as defined below) plus all unpaid interest credited thereon, shall be paid to such Director from the Director’s Grantor Trust in a lump sum within thirty (30) days following the date of such termination of service.

4.6 A “Change in Control” shall be deemed to have occurred on the earliest of the following dates:

(a) the date any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates) representing 20% or more of the combined voting power of the Company's then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (i) of paragraph (c) below; or

(b) the date the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the Effective Date, constitute the Board of Directors and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board of Directors or nomination for election by the Company's stockholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended; or

(c) the date on which there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other corporation or other entity, other than (i) a merger or consolidation (A) immediately following which the individuals who comprise the Board of Directors immediately prior thereto constitute at least a majority of the Board of Directors of the Company, the entity surviving such merger or consolidation or, if the Company or the entity surviving such merger or consolidation is then a subsidiary, the ultimate parent thereof and (B) which results in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, at least 50% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities Beneficially Owned by such Person any securities acquired directly from the Company or its Affiliates) representing 20% or more of the combined voting power of the Company's then outstanding securities; or

(d) the date the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company's assets, other than a sale or disposition by the Company of all or substantially all of the Company's assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by stockholders of the Company, in combination with the

ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, in substantially the same proportions as their ownership of the Company immediately prior to such sale.

Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of the common stock of the Company immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company immediately following such transaction or series of transactions.

For purposes of this Plan: “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act; “Beneficial Owner” shall have the meaning set forth in Rule 13d-3 under the Exchange Act; “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time; and “Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

4.7 A “Potential Change in Control” shall exist during any period in which the circumstances described in paragraph (a), (b), (c) or (d), below, exist (provided, however, that a Potential Change in Control shall cease to exist not later than the occurrence of a Change in Control):

(a) The Company enters into an agreement, the consummation of which would result in the occurrence of a Change in Control, provided that a Potential Change in Control described in this paragraph (a) shall cease to exist upon the expiration or other termination of all such agreements.

(b) Any Person (without regard to the exclusions set forth in clauses (i) through (iv) of such definition) publicly announces an intention to take or to consider taking actions the consummation of which would constitute a Change in Control; provided that a Potential Change in Control described in this paragraph (b) shall cease to exist upon the withdrawal of such intention, or upon a determination by the Board of Directors that there is no reasonable chance that such actions would be consummated.

(c) Any Person becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing 10% or more of either the then outstanding shares of common stock of the Company or the combined voting power of the Company’s then outstanding securities (not including any securities beneficially owned by such Person which are or were acquired directly from the Company or its Affiliates).

(d) The Board of Directors adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in Control exists; provided that a Potential Change in Control described in this paragraph (d) shall cease to exist upon a determination by the Board of Directors that the reasons that gave rise to the resolution providing for the existence of a Potential Change in Control have expired or no longer exist.

4.8 The provisions of Sections 4.5, 4.6, 4.7 and this Section 4.8 may not be amended or deleted, nor superseded by any other provision of this Plan, (i) during the pendency of a Potential Change in Control and (ii) during the period beginning on the date of a Change in Control and ending on the date five (5) years following such Change in Control.

## SECTION 5. CONVERSION TO COMMON STOCK UNITS

5.1 Any Director who is then serving as a director may, by written notice filed with the Secretary of the Company, irrevocably elect to have all or any portion of deferred fees previously earned but not yet paid, transferred from the Director's Deferred Fee Account to a stock account established under this Section 5 ("Stock Account"). Any election as to a portion of such fees shall be expressed as a percentage and the same percentage shall be applied to all such fees regardless of the calendar year in which earned or to all deferred fees earned in designated calendar years, as specified by the Director. A Director may make no more than one notional investment election under this Section 5.1 in any calendar year. All such elections may apply only to deferred fees for which an election has not previously been made and shall be irrevocable.

5.2 Any Director may, by written notice filed with the Secretary of the Company, elect to have all or any portion of deferred fees earned subsequent to the date such notice is filed credited to a Stock Account established under this Section 5. Fees covered by such election shall be credited to such account at the end of each calendar quarter in, or for which, such fees are earned. Such election may be revoked or modified by such Director, by written notice filed with the Secretary of the Company, as to deferred fees to be earned in calendar years subsequent to the calendar year such notice is filed, but shall be irrevocable as to deferred fees earned prior to such year.

5.3 Deferred fees credited to a Stock Account under Section 5.1 shall be converted to Common Stock Units by dividing the deferred fees so credited by the closing price of common stock of the Company on the date the notice of election under Section 5 is received by the Company (or the next business day, if there are no sales on such date) as reported on the New York Stock Exchange Composite Reporting System. Deferred fees credited to a Stock Account under Section 5.2 shall be converted to Common Stock Units by dividing the deferred fees so credited by the closing price of common stock of the Company as of the last business day of the calendar quarter for which the credit is made, as reported on the New York Stock Exchange Composite Reporting System.

5.4 Each Common Stock Unit shall be credited with (or adjusted for) the same cash and stock dividends, stock splits and other distributions and adjustments as are received by or applicable to one share of common stock of the Company. All cash dividends and other cash

distributions credited to Common Stock Units shall be converted to additional Common Stock Units by dividing each such dividend or distribution by the closing price of common stock of the Company on the payment date for such dividend or distribution, as reported by the New York Stock Exchange Composite Reporting System.

5.5 The value of the Common Stock Units credited each Director shall be paid to the Director in cash on the dates specified in Section 4.3 (or, if applicable, Section 4.5). The amount of each payment shall be determined by multiplying the Common Stock Units payable on each date specified in Section 4.3 (or, if applicable, Section 4.5) by the closing price of common stock of the Company on the day prior to the payment date (or the next preceding business day if there are no sales on such date), as reported by the New York Stock Exchange Composite Reporting System.

## SECTION 6. MISCELLANEOUS

6.1 Each Director or former Director entitled to payment of deferred fees hereunder from time to time may name any person or persons (who may be named contingently or successively) to whom any deferred Director's fees earned by him and payable to him are to be paid in case of his death before he receives any or all of such deferred Director's fees. Each designation will revoke all prior designations by the same Director or former Director, shall be in a form prescribed by the Company, and will be effective only when filed by the Director or former Director in writing with the Secretary of the Company during his lifetime. If a deceased Director or former Director shall have failed to name a beneficiary in the manner provided above, or if the beneficiary named by a deceased Director or former Director dies before him or before payment of all the Director's or former Director's deferred Directors' fees, the Company, in its discretion, may direct payment of the remaining installments required by Section 4.3 to either:

(a) any one or more or all of the next of kin (including the surviving spouse) of the Director or former Director, and in such proportions as the Company determines; or

(b) the legal representative or representatives of the estate of the last to die of the Director or former Director and his last surviving beneficiary.

The person or persons to whom any deceased Director's or former Director's deferred Directors' fees are payable under this Section will be referred to as his "beneficiary."

6.2 Establishment of the Plan and coverage thereunder of any person shall not be construed to confer any right on the part of such person to be nominated for reelection to the Board of Directors of the Company, or to be reelected to the Board of Directors.

6.3 Payment of deferred Directors' fees will be made only to the person entitled thereto in accordance with the terms of the Plan, and deferred Directors' fees are not in any way subject to the debts or other obligations of persons entitled thereto, and may not be voluntarily or

involuntarily sold, transferred or assigned. When a person entitled to a payment under the Plan is under legal disability or, in the Company's opinion, is in any way incapacitated so as to be unable to manage his financial affairs, the Company may direct that payment be made to such person's legal representative, or to a relative or friend of such person for his benefit. Any payment made in accordance with the preceding sentence shall be in complete discharge of the Company's obligation to make such payment under the Plan.

6.4 Any action required or permitted to be taken by the Company under the terms of the Plan shall be by affirmative vote of a majority of the members of the Board of Directors then in office.

6.5 To the extent applicable, it is intended that the Plan comply with the provisions of Section 409A of the Internal Revenue Code of 1986, as amended ("Code Section 409A"). The Plan will be administered and interpreted in a manner consistent with this intent, and any provision that would cause the Plan to fail to satisfy Code Section 409A will have no force and effect until amended to comply therewith (which amendment may be retroactive to the extent permitted by Code Section 409A). Notwithstanding anything contained herein to the contrary, for all purposes of this Plan, a Director shall not be deemed to have had a termination of service as a Director until the Director has incurred a separation from service as defined in Treasury Regulation §1.409A-1(h) and, to the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and applicable guidance issued thereunder, payment of the amounts payable under the Plan that would otherwise be payable during the six-month period after the date of termination shall instead be paid on the first business day after the expiration of such six-month period, plus interest thereon, at a rate equal to the rate specified in Section 8.8 (to the extent that such interest is not already provided to the Director under Section 8.10), from the respective dates on which such amounts would otherwise have been paid until the actual date of payment. In addition, for purposes of the Plan, each amount to be paid and each installment payment shall be construed as a separate identified payment for purposes of Code Section 409A.

## SECTION 7. AMENDMENT AND DISCONTINUANCE

While the Company expects to continue the Plan, it must necessarily reserve, and does hereby reserve, the right to amend or discontinue the Plan at any time; provided, however, that any amendment or discontinuance of the Plan shall be prospective in operation only, and shall not affect the payment of any deferred Directors' fees theretofore earned by any Director, or the conditions under which any such fees are to be paid or forfeited under the Plan. Any discontinuance of the Plan by the Company shall comply with the requirements of Code Section 409A.

## SECTION 8. ALTERNATE PAYMENT OF FEES

8.1 A Director who was first elected or appointed to the Board of Directors before January 1, 2016 may, by written notice filed with the Secretary of the Company prior to each calendar year, elect to receive all or a portion of his fees earned in the following calendar year in

accordance with the provisions of Section 8. An election under this Section 8.1 shall become irrevocable as of December 31 of the calendar year prior to the year in which such monthly and meeting fees will be earned (or, in the case of a new Director elected or appointed before January 1, 2016, on the 30th day following the Director's first participation in the Plan and all plans that would be aggregated with the Plan pursuant to Treasury Regulation §1.409A-1(c)(2)(i), provided that the compensation subject to such election relates solely to services performed after the date of such election).

8.2 If payment of a Director's fees is made pursuant to Section 8.1, such fees shall not be deferred and a portion of the gross amount of such fees shall be paid currently in cash for the Director directly to a "Grantor Trust" established by the Director, provided such trust is in a form determined by the Committee; and the balance of the gross amount of such fees shall be paid currently in cash directly to the Director, provided that the portion paid directly to the Director shall be an amount equal to the aggregate federal, state and local individual income taxes attributable to the gross fees paid pursuant to this Section 8.2 (determined in accordance with Section 8.14). In no event shall such fees be paid to the Grantor Trust or directly to the Director later than the last day of the "applicable 2½ month period," as such term is defined in Treasury Regulation §1.409A-1(b)(4)(i)(A).

8.3 The Company will establish and maintain four separate accounts in the name of each Director who has made an election under Section 8.1 as follows: a "Pre-Tax Fee Account," an "After-Tax Fee Account," a "Pre-Tax Stock Account" and an "After-Tax Stock Account" (collectively, the "Accounts").

(a) The Pre-Tax Fee Account shall reflect the total amount of any fees paid in cash to a Director or deposited to a Director's Grantor Trust, including the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2, and Interest to be credited to a Director pursuant to Section 8.8. The After-Tax Fee Account shall reflect such gross amounts but shall be maintained on an after-tax basis.

(b) The Pre-Tax Stock Account shall reflect the total amount of fees converted to Common Stock Units pursuant to Section 5, including the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2, and any adjustments made pursuant to Section 8.9. The After-Tax Stock Account shall reflect such gross amounts but shall be maintained on an after-tax basis.

(c) The Accounts established pursuant to this Section 8.3 are for the convenience of the administration of the Plan and no trust relationship with respect to such Accounts is intended or should be implied.

8.4 As of the end of each calendar year, the Company shall adjust each Director's Pre-Tax Fee Account as follows:

(a) FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an amount equal to the distribution from the

fee account maintained thereunder that would have been made to the Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3;

(b) NEXT, credit an amount equal to the gross amount of any fees paid for that year, not converted to Common Stock Units, that are paid to the Director (including the amount deposited in the Director's Grantor Trust and the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2) according to Section 8.2; and

(c) FINALLY, credit an amount equal to the Interest earned for that year according to Section 8.8.

8.5 As of the end of each calendar year, the Company shall adjust each Director's After-Tax Fee Account as follows:

(a) FIRST, charge, in any year in which the Director is in receipt of a benefit distribution from his or her Grantor Trust, an amount equal to the product of (i) the distribution that would have been made to the Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3, multiplied by (ii) a fraction, the numerator of which is the balance in the Director's After-Tax Fee Account as of the end of the prior fiscal year and the denominator of which is the balance of the Director's Pre-Tax Fee Account as of that same date;

(b) NEXT, credit an amount equal to the fees not converted to Common Stock Units that are paid that year to the Director directly to the Director's Grantor Trust according to Section 8.2; and

(c) FINALLY, credit an amount equal to the After-Tax Interest earned for that year according to Section 8.8.

8.6 As of the end of each calendar year, the Company shall adjust each Director's Pre-Tax Stock Account as follows:

(a) FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an amount equal to the distribution that would have been made to the Director if the aggregate amount of fees paid according to Section 8.2 had instead been deferred under Section 3 and the adjustments had been made under Section 5;

(b) NEXT, credit an amount equal to the total amount of any fees for that year that are converted to Common Stock Units and paid to the Director (including the amount deposited in the Director's Grantor Trust and the amount equal to the aggregate federal, state and local individual income taxes attributable to the fees paid pursuant to Section 8.2) and allocated to the Stock Account maintained thereunder) according to Section 8.2; and

(c) NEXT, credit an amount equal to the net earnings of the Director's Grantor Trust for the year; and

(d) FINALLY, credit an amount equal to the Book Value Adjustments to be made for that year according to Section 8.9.

8.7 As of the end of each calendar year, the Company shall adjust each Director's After-Tax Stock Account as follows:

(a) FIRST, charge, in any year in which the Director is entitled to receive a distribution from his or her Grantor Trust, an amount equal to the product of (i) the distribution that would have been made to the Director if the aggregate amounts paid according to Section 8.2 had instead been deferred under Section 3 and the adjustments had been made under Section 5, multiplied by (ii) a fraction, the numerator of which is the balance in the Director's After-Tax Stock Account as of the end of the prior fiscal year and the denominator of which is the balance of the Director's Pre-Tax Stock Account as of that same date;

(b) NEXT, credit an amount equal to the fees converted to Common Stock Units that are paid that year to the Director directly to the Director's Grantor Trust and allocated to the Stock Account maintained thereunder according to Section 8.2; and

(c) NEXT, credit an amount equal to the net earnings of the Director's Grantor Trust for the year; and

(d) FINALLY, credit an amount equal to the Book Value Adjustments to be made for that year according to Section 8.9.

8.8 The Director's Pre-Tax Fee Account and After-Tax Fee Account shall be credited with interest as follows:

(a) As of the end of each calendar year, a Director's Pre-Tax Fee Account shall be credited with interest ("Interest") at the following rate:

(i) the average of the "prime rate" of interest set forth on the Bloomberg Screen BTMM or comparable successor quotation service on the first business day of January and the last business day of each month of the fiscal year; plus

(ii) two hundred twenty-five (225) basis points.

(b) As of the end of each calendar year, a Director's After-Tax Fee Account shall be credited with the amount of Interest set forth above, multiplied by (one minus the aggregate of the applicable federal, state and local individual income tax rates and employment tax rate) (the "After-Tax Interest").

8.9 As of the end of each calendar year, a Director's Pre-Tax Stock Account and After-Tax Stock Account shall be adjusted as provided in Section 5.4, to the extent applicable, and shall also be adjusted to reflect the increase or decrease in the fair market value of the Company's common stock determined in accordance with Section 5.5, except that (i) any reference to the payment date in such Section shall mean December 31 of the applicable calendar year for purposes of this Section, and (ii) adjustments to the After-Tax Stock Account shall be made on an after-tax basis. Such adjustments shall be referred to as "Book Value Adjustments."

8.10 In addition to any fees paid to a Director's Grantor Trust under Section 8.2 during the year, the Company shall also make a payment (an "Interest Payment") with respect to each Director who has established a Grantor Trust for each year in which the Grantor Trust is in effect. The Interest Payment shall equal the excess, if any, of the gross amount of the Interest credited to the Director (as defined in Section 8.8(a)), over the net earnings of the Director's Grantor Trust for the year, and shall be paid within the thirty (30)-day period beginning April 1 of the following calendar year. A portion of such gross Interest Payment, equal to the excess, if any, of the Net Interest Accrual over the net earnings of the Director's Grantor Trust, shall be deposited in the Director's Grantor Trust, with the balance paid to the Director; provided, however, in the event that the net earnings of the Director's Grantor Trust exceeds the Net Interest Accrual, a distribution from the Grantor Trust shall be required in accordance with Section 8.15. A Director's Net Interest Accrual for a year is an amount equal to the After-Tax Interest credited to the Director's After-Tax Fee Account for that year in accordance with Section 8.8(b).

8.11 In addition to the fees paid under Section 8.2 during the year and the Interest Payment described above, the Company shall also make a payment (a "Principal Payment") with respect to each Director who has established a Grantor Trust for each year in which the Grantor Trust is in effect, to be credited to the Stock Account maintained thereunder. The Principal Payment shall equal the excess, if any, of 75 percent of the fair market value (as determined in accordance with Section 6.5) of the balance of the Director's Pre-Tax Stock Account on December 31 over the balance in the Stock Account maintained under the Director's Grantor Trust as of that same date, and shall be paid within the thirty (30)-day period beginning April 1 of the following calendar year. For the calendar year in which the last installment distribution is made from the Director's Grantor Trust (meaning, the year that is X years following the year of the event triggering the payments, where X is the same number of years served by the Director), the payment made under this Section 8.11 shall equal the excess, if any, of 100 percent of the balance of the Director's After-Tax Stock Account over the balance in the Stock Account maintained under the Director's Grantor Trust as of that same date.

8.12 Each Director's Grantor Trust assets shall be invested solely in the instruments specified by investment guidelines established by the Committee. Such investment guidelines, once established, may be changed by the Committee, provided that any change shall not take effect until the year following the year in which the change is made and provided further that the instruments specified shall be consistent with the provisions of Section 3(b) of the form of Grantor Trust established by the Committee.

8.13 For purposes of Section 8, a Director's federal income tax rate shall be deemed to be the highest marginal rate of federal individual income tax in effect in the calendar year in which a calculation under this Section is to be made and state and local tax rates shall be deemed to be the highest marginal rates of individual income tax in effect in the state and locality of the Director's residence on the date such a calculation is made, net of any federal tax benefits without a benefit for any net capital losses. Notwithstanding the preceding sentence, if a Director is not a citizen or resident of the United States, his or her income tax rates shall be deemed to be the highest marginal income tax rates actually imposed on the Director's benefits under this Plan or earnings under his or her Grantor Trust without a benefit for any net capital losses.

8.14 If a portion of a Director's fees have been paid to a Grantor Trust pursuant to Section 8.2, then those fees and earnings thereon shall be paid to him from the Grantor Trust in the order in which they were earned (i.e., the fees for the earliest year of service as a Director will be the first fees distributed from the Grantor Trust(s), the fees for the next earliest year of service as a Director will be paid on the anniversary of the payment of the first installment, etc.). The distribution of a Director's fees shall continue until all fees which the Director is entitled to receive under the Plan shall have been paid in accordance with the terms of the Grantor Trust(s).

8.15 AbbVie, as the administrator of the Director's Grantor Trust, may direct the trustee to distribute to the Director from the income of such Grantor Trust, a sum of money sufficient to pay the taxes on trust earnings for such year, to the extent a sufficient sum of money has not been paid to the Director pursuant to Section 8.10 or 8.11, as applicable. The taxes shall be determined in accordance with Section 8.13.

8.16 AbbVie, as the administrator of the Director's Grantor Trust, may direct the trustee to pay the appropriate federal, state and local individual income taxes attributable to the fees and other payments paid to the Director pursuant to Sections 8.2, 8.10 and 8.11 to the applicable tax authorities on behalf of the Director. The taxes shall be determined in accordance with Section 8.13.

**Certification of Chief Executive Officer  
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))**

I, Richard A. Gonzalez, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AbbVie Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report;
4. AbbVie's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for AbbVie and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of AbbVie's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in AbbVie's internal control over financial reporting that occurred during AbbVie's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie's internal control over financial reporting; and
5. AbbVie's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie's auditors and the audit committee of AbbVie's board of directors:
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie's internal control over financial reporting.

Date: November 6, 2019

/s/ Richard A. Gonzalez

\_\_\_\_\_  
Richard A. Gonzalez, Chairman of the Board  
and Chief Executive Officer

**Certification of Chief Financial Officer  
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))**

I, Robert A. Michael, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AbbVie Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report;
4. AbbVie's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for AbbVie and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of AbbVie's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in AbbVie's internal control over financial reporting that occurred during AbbVie's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie's internal control over financial reporting; and
5. AbbVie's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie's auditors and the audit committee of AbbVie's board of directors:
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie's internal control over financial reporting.

Date: November 6, 2019

/s/ Robert A. Michael

\_\_\_\_\_  
Robert A. Michael, Executive Vice President,  
Chief Financial Officer

**Certification Pursuant To  
18 U.S.C. Section 1350  
As Adopted Pursuant To  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of AbbVie Inc. (the "Company") on Form 10-Q for the period ended September 30, 2019 as filed with the Securities and Exchange Commission (the "Report"), I, Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard A. Gonzalez

---

Richard A. Gonzalez

Chairman of the Board and Chief Executive Officer

November 6, 2019

A signed original of this written statement required by Section 906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

**Certification Pursuant To  
18 U.S.C. Section 1350  
As Adopted Pursuant To  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of AbbVie Inc. (the "Company") on Form 10-Q for the period ended September 30, 2019 as filed with the Securities and Exchange Commission (the "Report"), I, Robert A. Michael, Executive Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert A. Michael

Robert A. Michael

Executive Vice President, Chief Financial Officer

November 6, 2019

A signed original of this written statement required by Section 906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.